[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 180
1. Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, Bacchi CE, Seuánez HN, Zalcberg IR: Epstein-Barr virus (EBV) detection and typing by PCR: a contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol; 2006 Aug 07;1:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a systematic comparison between RISH and PCR for EBV detection, in a group of childhood B-cell Non-Hodgkin lymphomas (NHL), aiming to validate PCR as a first, rapid method for the diagnosis of EBV-associated B-cell NHL.
  • METHODS: EBV infection was investigated in formalin fixed paraffin-embedded tumor samples of 41 children with B-cell NHL, including 35 Burkitt's lymphoma (BL), from Rio de Janeiro, Brazil, by in situ hybridization of EBV-encoded small RNA (EBER-RISH) and PCR assays based on EBNA2 amplification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 Aug;141(2):457-65 [1323222.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1259-65 [1661073.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Cell. 1988 Jan 15;52(1):51-61 [2830981.001]
  • [Cites] J Pathol. 1995 Mar;175(3):263-71 [7745495.001]
  • [Cites] J Virol. 1994 Nov;68(11):7374-85 [7933121.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):604-11 [7967515.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):239-52 [8053485.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pediatr Pathol. 1994 Jan-Feb;14(1):101-9 [8159607.001]
  • [Cites] Med Pediatr Oncol. 1993;21(1):36-42 [8381202.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1045-55 [8562929.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] J Virol. 1996 May;70(5):3286-9 [8627812.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1245-52 [8630905.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3949-55 [10339504.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):79-87 [12766612.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2852-7 [10449464.001]
  • [Cites] Arch Pathol Lab Med. 2002 Mar;126(3):331-5 [11860309.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):329-37 [11342313.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1098-100 [10539915.001]
  • (PMID = 16893464.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082274
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1559641
  •  go-up   go-down


2. Muroyama Y, Fujiwara Y, Orkin SH, Rowitch DH: Specification of astrocytes by bHLH protein SCL in a restricted region of the neural tube. Nature; 2005 Nov 17;438(7066):360-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well established that cellular diversification of neurons in the embryo is generated by position-dependent extrinsic signals and combinatorial interactions of transcription factors that direct specific cell fates by suppressing alternative fates.
  • Here we show multiple functions of Stem cell leukaemia (Scl, also known as Tal1), which encodes a basic helix-loop-helix (bHLH) transcription factor, in the regulation of both astrocyte versus oligodendrocyte cell fate acquisition and V2b versus V2a interneuron cell fate acquisition in the p2 domain of the developing vertebrate spinal cord.
  • [MeSH-major] Astrocytes / cytology. Astrocytes / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Differentiation. DNA-Binding Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Spinal Cord / embryology. Spinal Cord / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Cell Lineage. Chick Embryo. Gene Expression Regulation, Developmental. Interneurons / cytology. Interneurons / metabolism. Mice. Motor Neurons / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Oligodendroglia / cytology. Oligodendroglia / metabolism. Stem Cells / cytology. Stem Cells / metabolism


3. Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC: The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis. Mol Cell Biol; 2005 Mar;25(6):2395-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human ETS family gene TEL2/ETV7 is highly homologous to TEL1/ETV6, a frequent target of chromosome translocations in human leukemia and specific solid tumors.
  • Although TEL2 is infrequently up-regulated in human sporadic Burkitt's lymphoma, analysis of pediatric B-cell acute lymphocytic leukemia (B-ALL) samples showed increased coexpression of TEL2 and MYC and/or MYCN in over one-third of B-ALL patients.
  • Therefore, TEL2 and MYC also appear to cooperate in provoking a cadre of human B-cell malignancies.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Clin Cancer Res. 1997 Jul;3(7):1067-76 [9815785.001]
  • [Cites] Oncol Rep. 1999 Jul-Aug;6(4):859-63 [10373671.001]
  • [Cites] J Pathol. 1999 Mar;187(4):403-9 [10398098.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):30132-8 [10514502.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2670-7 [10541553.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):871-7 [10544023.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3341-8 [10828014.001]
  • [Cites] Neoplasia. 1999 Dec;1(6):526-36 [10935500.001]
  • [Cites] Oncogene. 2000 Sep 28;19(41):4802-6 [11032031.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6524-32 [11175368.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):9421-36 [11108721.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):595-601 [11332715.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5063-70 [11438662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9654-9 [11481442.001]
  • [Cites] J Mol Med (Berl). 2002 Mar;80(3):137-46 [11894140.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):905-14 [12718877.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2000;65:499-510 [12760067.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):46378-86 [12960174.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6091-100 [15342392.001]
  • [Cites] Science. 1983 Oct 28;222(4622):390-3 [6414084.001]
  • [Cites] Nature. 1984 Jan 26-Feb 1;307(5949):334-40 [6420706.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Cell. 1986 Oct 10;47(1):11-8 [3093082.001]
  • [Cites] Mol Cell Biol. 1987 Apr;7(4):1436-44 [3037318.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:37-43 [1490376.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1717-23 [7753548.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3840-7 [7791791.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4263-9 [7492786.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):381-91 [8627151.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2891-9 [8639909.001]
  • [Cites] Curr Top Microbiol Immunol. 1997;220:67-79 [9103676.001]
  • [Cites] Nat Genet. 1997 Apr;15 Spec No:417-74 [9140409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7245-50 [9207076.001]
  • [Cites] Oncogene. 1997 Jul 10;15(2):203-11 [9244355.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4374-83 [9250681.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1777-86 [9292510.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 17;1377(2):F1-11 [9606973.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2392-402 [9694803.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):124-5 [9744267.001]
  • (PMID = 15743832.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076379; United States / NCI NIH HHS / CA / R01 CA76379-07; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01-CA72999-08
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETV7 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Proto-Oncogene Proteins c-myc; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1061619
  •  go-up   go-down


Advertisement
4. Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH: A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia; 2007 Jul;21(7):1405-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is present at high surface density on chronic B-lymphocytic leukemia (B-CLL) cells and cells of other B-cell malignancies, and is a prime target for therapy with antibody-derived agents.
  • This fusion protein induced efficient antigen-restricted apoptosis of several human leukemia- and lymphoma-derived cell lines including Nalm-6, which it eliminated at an effective concentration (EC(50)) of 2.5 nM.
  • The agent displayed synergistic toxicity when used in combination with valproic acid and cyclosporin A in cell-culture assays.
  • It induced apoptosis of primary malignant cells in 12/12 samples from B-CLL patients, including patients responding poorly to fludarabine, and of cells from one pediatric acute lymphoblastic leukemia patient.
  • [MeSH-major] Antigens, CD19 / drug effects. Apoptosis / drug effects. Immunotoxins / pharmacology. Leukemia, B-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495978.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Exotoxins; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


5. Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group: The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer; 2008 Aug;51(2):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
  • BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades.
  • Among 18 patients who had a chemotherapy-sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, B-Cell / therapy. Lymphoma, B-Cell / therapy


6. Spinola-Castro AM, Siviero-Miachon AA, Andreoni S, Tosta-Hernandez PD, Macedo CR, Lee ML: Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited. Clin Adv Hematol Oncol; 2009 Jul;7(7):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient hyperglycemia during childhood acute lymphocytic leukemia chemotherapy: an old event revisited.
  • Hyperglycemia has been described as a common event occurring during acute lymphocytic leukemia chemotherapy.
  • Our goal was to compare clinical and laboratory findings between hyperglycemic episodes occurring during childhood acute lymphocytic leukemia induction chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Glucocorticoids / adverse effects. Hyperglycemia / chemically induced. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701154.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / Glucocorticoids; EC 3.2.1.- / Amylases
  •  go-up   go-down


7. Molina F, Schramm C, Ruiz G: [Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile]. Rev Med Chil; 2009 Dec;137(12):1553-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Direct costs of pharmacotherapy for acute leukemia at a Regional Hospital in Chile].
  • BACKGROUND: In Chile, leukemia is one of the diseases whose treatment is guaranteed by a special law called AUGE (universal access and explicit guaranties).
  • AIM: To determine and to characterize the direct costs of pharmacotherapy for leukemia at a regional hospital in Chile.
  • MATERIAL AND METHODS: Data were retrospectively obtained from electronic and manual records of the hospital for all patients treated for leukemia between 2003 and 2006.
  • Patients were classified into four groups: pediatric and adult patients treated for acute lymphocytic leukemia (ALL children and ALL adults, respectively), and pediatric and adult patients treated for acute myelogenous leukemia (AML children and AML adults, respectively).
  • RESULTS: Total accumulated costs of pharmacotherapy for acute leukemia between 2003 and 2006 were 304,724,845 Chilean pesos (USD 574,952).
  • CONCLUSIONS: Annual costs of pharmacotherapy per patient for acute leukemia in this regional hospital were approximately USD 4,717.
  • [MeSH-major] Antineoplastic Agents / economics. Health Care Costs / statistics & numerical data. Leukemia, Myeloid, Acute / economics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361130.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Hochman E, Kinston S, Harmelin A, Göttgens B, Izraeli S: The SCL 3' enhancer responds to Hedgehog signaling during hemangioblast specification. Exp Hematol; 2006 Dec;34(12):1643-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cell leukemia (SCL), a basic helix-loop-helix (bHLH) transcription factor, is essential for the specification and function of the hemangioblast.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157160.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0800784
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Gli protein, mouse; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 0 / Zinc Finger Protein GLI1
  •  go-up   go-down


9. Cowan SA: Denmark decides not to introduce hepatitis B into the childhood vaccination programme. Euro Surveill; 2005;10(11):E051103.3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denmark decides not to introduce hepatitis B into the childhood vaccination programme.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794274.001).
  • [ISSN] 1560-7917
  • [Journal-full-title] Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
  • [ISO-abbreviation] Euro Surveill.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


10. Forsythe A, Breland T, Majumdar S, Elkin TD, Johnson D, Megason G: Gender differences in incidence rates of childhood B-precursor acute lymphocytic leukemia in Mississippi. J Pediatr Oncol Nurs; 2010 May-Jun;27(3):164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in incidence rates of childhood B-precursor acute lymphocytic leukemia in Mississippi.
  • The authors studied pediatric patients with B-precursor acute lymphocytic leukemia (ALL) to determine whether Mississippi's gender incidences correlate with national statistics.
  • A retrospective chart review was performed of pediatric B-precursor ALL patients diagnosed at the Children's Cancer Clinic at the University of Mississippi Medical Center from 1995 to 2005.
  • However, the national average includes T-cell ALL, which is known to be significantly more prevalent in boys.
  • Of greater significance, boys were noted to present with high-risk B-precursor ALL 4 times more than girls, suggesting the need for further investigation into possible causes of this phenomenon.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Academic Medical Centers. Bias (Epidemiology). Causality. Chi-Square Distribution. Child. Female. Humans. Incidence. Male. Mississippi / epidemiology. Population Surveillance. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Prevalence. Retrospective Studies. Risk Assessment. Sex Distribution. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20164246.001).
  • [ISSN] 1532-8457
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D, Saverino D, Zarcone D, De Rossi G, Ciccone E, Grossi CE: CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia; 2005 Apr;19(4):551-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.
  • Acute lymphoblastic leukemia (ALL) is the most frequent malignancy of childhood.
  • We investigated CD1d expression in 80 pediatric B-cell precursor (BCP) ALL cases defined according to immunophenotype, cytogenetic features and age at onset.
  • CD1d+ ALLs were significantly associated with infant leukemia, pro-B phenotype and mixed-lineage leukemia (MLL)/AF4 gene rearrangement.
  • [MeSH-major] Antigens, CD1 / metabolism. Hematopoietic Stem Cells / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antigens, CD1d. B-Lymphocytes / cytology. Biomarkers, Tumor / metabolism. Cell Communication. Cell Line. Child. Galactosylceramides / metabolism. Humans. Infant. Killer Cells, Natural / cytology. Killer Cells, Natural / metabolism. Predictive Value of Tests. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744356.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD1d; 0 / Biomarkers, Tumor; 0 / CD1D protein, human; 0 / Galactosylceramides; 0 / alpha-galactosylceramide
  •  go-up   go-down


12. Menon R, Muzumdar D, Shah A, Goel A: Glioblastoma multiforme following cranial irradiation and chemotherapy for acute lymphocytic leukaemia. Report of 3 cases. Pediatr Neurosurg; 2007;43(5):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme following cranial irradiation and chemotherapy for acute lymphocytic leukaemia. Report of 3 cases.
  • The occurrence of glioblastoma multiforme following radiation and chemotherapy in acute lymphocytic leukaemia (ALL) is rare.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cranial Irradiation / adverse effects. Glioblastoma / pathology. Neoplasms, Radiation-Induced / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17786001.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic
  •  go-up   go-down


13. Hill A, Short MA, Varghese C, Kusumakumary P, Kumari P, Morgan GJ: The t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Kerala, Southern India. Haematologica; 2005 Mar;90(3):414-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The t(12:21) is underrepresented in childhood B-lineage acute lymphoblastic leukemia in Kerala, Southern India.
  • t(12;21) (TEL/AML1) is the most common genetic event in childhood B-cell acute lymphoblastic leukemia (B-ALL) in Western countries.
  • [MeSH-major] Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 21. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Child. Humans. Incidence. India / epidemiology. Leukemia, B-Cell. Molecular Epidemiology


14. Jetsrisuparb A, Wiangnon S, Komvilaisak P, Kularbkaew C, Yutanawiboonchai W, Mairieng E: Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma. J Pediatr Hematol Oncol; 2005 Apr;27(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma.
  • This report is the first to describe the successful treatment of a 14-year-old boy with aggressive recurrent, CD20-positive, B-cell large cell non-Hodgkin's lymphoma.
  • Rituximab and CHOP in addition to chemotherapy may be an alternative treatment for aggressive recurrent, pediatric CD20-positive B-cell large cell non-Hodgkin's lymphoma if highly intensive chemotherapy and stem cell transplantation are not available.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838396.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Li YQ, Wu XL, Yang LJ, Chen SH, Geng SX, Przybylski G, Schmidt CA: [Thymic recent output function in patients with B-cell lymphocytic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1023-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thymic recent output function in patients with B-cell lymphocytic malignancies].
  • The aim of the study was to analyze the naive T cell level of thymic recent output in patients with B-cell malignancies, thereby to evaluate the potential T-cell function.
  • Quantitative analysis of T-cell receptor rearrangement excision circles (TRECs) in DNA of peripheral blood mononuclear cells from 61 cases of B-cell lymphocytic malignancy (including 20 cases of adult B-ALL, 6 case of childhood B-ALL, 4 cases of B-CLL, 17 cases of B-NHL and 14 cases of MM) were preformed by real-time PCR (TaqMan), and TREC-level was detected according to the number of CD3-positive cells.
  • The mean value of TRECs was 0.53 +/- 1.52 copies/1000 PBMNC and 2.01 +/- 3.93 copies/1000 CD3+ cells in adult B-ALL (p = 0.0005, p = 0.0123), 0.11 +/- 0.15 copies/1000 PBMNC and 0.23 +/- 0.27 copies/1000 CD3+ cells in B-CLL (p = 0.0015, p = 0.0381), 0.71 +/- 1.34 copies/1000 PBMNC in B-NHL (p = 0.0017), 0.53 +/- 0.90 copies/1000 PBMNC in MM patients (p = 0.0018), as compared with 3.76 +/- 3.42 copies/1000 PBMNC and 5.87 +/- 4.96 copies/1000 CD3+ cells in normal individuals, the TREC level was significantly decreased in all groups of B-cell lymphocytic malignancy, as well as in ALL-CR group.
  • However, the TREC level in childhood B-ALL was significant higher than those in adult B-ALL group.
  • It is concluded that the function of thymic recent outputting naive T cells in B-cell malignancies significantly decreases, however, the individual difference of thymic output function is obvious.
  • The thymic recent output function can not be recovered during CR phase in patients with B-cell malignancies, so that dynamic analysis of TREC level is necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956683.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Schoumans J, Johansson B, Corcoran M, Kuchinskaya E, Golovleva I, Grandér D, Forestier E, Staaf J, Borg A, Gustafsson B, Blennow E, Nordgren A: Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2. Br J Haematol; 2006 Nov;135(4):492-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2.
  • Although the dic(9;20)(p11-13;q11) is a recurrent chromosomal abnormality in paediatric B-cell precursor acute lymphoblastic leukaemia (BCP ALL), occurring in approximately 2% of the cases, its molecular genetic consequences have not been elucidated.
  • In the present study, high-resolution genome-wide array-based comparative genomic hybridisation (array-CGH) and fluorescence in situ hybridisation (FISH) were used to characterise the 9p and 20q breakpoints (BPs) in seven childhood BCP ALLs with dic(9;20), which was shown to be unbalanced in all of them, resulting in loss of 9p13.2-pter.
  • One of the ALLs, shown to have a complex dic(9;20), was further investigated by FISH, revealing a rearrangement of the haemapoietic cell kinase isoform p61 (HCK) gene at 20q11.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999846.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


17. Steiner M, Attarbaschi A, König M, Nebral K, Gadner H, Haas OA, Mann G, Austrian Berlin-Frankfurt-Münster Group: Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome. Pediatr Hematol Oncol; 2005 Apr-May;22(3):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • Accordingly, they were able to analyze 8 of 10 individuals with DS and a BCP ALL, two of whom who suffered from a TEL/AML1+ leukemia.
  • Based on this observation they concluded that individuals with BCP leukemia and a constitutional trisomy 21 may have similar likelihood to have a TEL/AML1 rearrangement as BCP ALL patients without this specific predisposing factor.
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Pediatr Hematol Oncol. 2005 Jan-Feb;22(1):11-6 [15770827.001]
  • (PMID = 16020107.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


18. Stefan DC, Stones D: How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma; 2009 Feb;50(2):196-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hodgkin lymphoma (HL) is a common B-cell childhood neoplasm and it has a higher incidence in the 0-14 year age group in developing countries compared to developed countries.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Feb;50(2):152-3 [19235011.001]
  • (PMID = 19197725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Ahmad N, Zaidi A, Badar F, Maaz AU, Akram MS: Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol; 2010 Mar;6(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
  • AIM: To analyze the clinical characteristics of B-cell non-Hodgkin's lymphoma (NHL) patients and the therapeutic efficacy of French-American-British Lymphoma Malins de Burkitt 96 and the recent United Kingdom Children's Cancer Study Group B-cell NHL guidelines in the tertiary care hospital of a developing country.
  • METHODS: Patients aged < or =18 years registered at our hospital between January 1995 and December 2006 with histologically proved B-Cell NHL were selected for retrospective analysis.
  • Of these 95 had Burkitt's lymphoma, 22 diffuse large B-cell lymphoma and five had B-cell NHL not otherwise specified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Practice Guidelines as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398038.001).
  • [ISSN] 1743-7563
  • [Journal-full-title] Asia-Pacific journal of clinical oncology
  • [ISO-abbreviation] Asia Pac J Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Olgar S, Yetgin S, Cetin M, Aras T, Akhan O: Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period. J Pediatr Hematol Oncol; 2005 Apr;27(4):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrolyte abnormalities at diagnosis of acute lymphocytic leukemia may be a clue for renal damage in long-term period.
  • The objective of this study was to determine the frequency of electrolyte perturbations and their relationship with leukemic status before and after chemotherapy in patients with acute lymphocytic leukemia.
  • Electrolyte abnormalities and renal changes were commonly observed before and after therapy for leukemia.
  • [MeSH-major] Kidney Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Water-Electrolyte Imbalance / etiology

  • MedlinePlus Health Information. consumer health - Fluid and Electrolyte Balance.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838391.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / beta 2-Microglobulin
  •  go-up   go-down


21. Liu Y, Li ZG, Zhao W, Li B, Gong WY, Wu MY: [Immunophenotypic characteristics of children with acute lymphoblastic leukemia carrying TEL-AML1 fusion gene]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):714-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotypic characteristics of children with acute lymphoblastic leukemia carrying TEL-AML1 fusion gene].
  • To investigate the immunological and other clinical characteristics in TEL/AML1+ childhood B-acute lymphoblastic leukemia (B-ALL), immunophenotyping was performed with three-color flow cytometry, and the expression of TEL-AML1 fusion gene was detected with nested RT-PCR.
  • (2) compared with TEL-AML1- group, no significant difference was found in age, gender, white cell count and blasts count in peripheral blood of TEL-AML1+;.
  • It is concluded that TEL-AML1 rearrangement is a frequent molecular abnormality in childhood ALL.
  • These characteristics may be useful in detection of minimal residual leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928306.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Core Binding Factor Alpha 2 Subunit; 0 / HLA-DR Antigens; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


22. Wang XD, Chen J: [Aml1 gene abnormality in pediatric acute leukemia-review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug;17(4):1078-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aml1 gene abnormality in pediatric acute leukemia-review].
  • Acute leukemia, the most common cancer in childhood, affects children's health severely, whereas the pathogeny and mechanism have not been elucidated clearly yet.
  • As many studies showed, it has been found that transformation of cytogenetics plays a crucial role in leukemia development, and is frequently involved in the transforming action of aml1 gene, one of which is essential for regulation of normal hematogenesis.
  • Moreover, in children acute leukemia, more than one third children with acute leukemia can be detected with dysfunction of the aml1 gene.
  • Our findings highlight the translocation of aml1 gene in children acute leukemia, indicating its mechanism, especailly provide a new target for clinical diagnosis and therapy.
  • In this review, the structure and function of aml1 gene, the abnormality of aml1 gene in acute lymphocytic leukemia, abnormality of aml1 gene in acute myeloid leukemia and so on were summarized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698265.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


23. Handgretinger R: The role of graft-versus-host disease in the inhibition of normal B-lymphopoiesis and leukemic control of B-lineage acute lymphocytic leukemia after allogeneic stem cell transplantation. Haematologica; 2006 Mar;91(3):292B
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of graft-versus-host disease in the inhibition of normal B-lymphopoiesis and leukemic control of B-lineage acute lymphocytic leukemia after allogeneic stem cell transplantation.
  • [MeSH-major] B-Lymphocyte Subsets / cytology. Burkitt Lymphoma / blood. Burkitt Lymphoma / pathology. Graft vs Host Disease / blood. Lymphopoiesis / physiology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2006 Mar;91(3):340-7 [16531257.001]
  • (PMID = 16531250.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica; 2007 Aug;92(8):1043-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: Impaired apoptosis, mediated by members of the inhibitor of apoptosis proteins (IAP) family such as survivin, is thought to contribute to leukemic cell survival.
  • To date, however, there is no information available on the prognostic role of survivin in pediatric precursor B-cell acute lymphocytic leukemia (BCP-ALL), the most frequent malignancy in childhood.
  • DESIGN AND METHODS: In a retrospective study including 66 pediatric patients we analyzed the impact of survivin protein levels on outcome in BCP-ALL.
  • [MeSH-major] Inhibitor of Apoptosis Proteins / analysis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640858.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


25. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, Cheng C, Panetta JC, Pui CH, Relling MV, Cheok MH, Evans WE: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med; 2008 Apr 15;5(4):e83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
  • BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.
  • Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells.
  • METHODS AND FINDINGS: We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial "up-front" in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX.
  • We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX.
  • CONCLUSIONS: Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.
  • TRIAL REGISTRATIONS: Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):93-9 [14693814.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95 [12972803.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Vitam Horm. 2003;66:403-56 [12852262.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):775-81 [12618889.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2423-9 [12114448.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1832-9 [16936229.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Biochem Pharmacol. 1999 Aug 15;58(4):539-55 [10413291.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1067-74 [9920857.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5638-44 [2458828.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 18;88(18):1255-6 [8797761.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Haematologica. 2001 Feb;86(2):121-7 [11224479.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • (PMID = 18416598.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00137111
  • [Grant] United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2292747
  •  go-up   go-down


26. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, Faini A, Veltroni M, Husak D, Schumich A, Ratei R, Biondi A, Dworzak MN, I-BFM-ALL-FCM-MRD-Study Group: Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom; 2008 May;74(3):150-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
  • BACKGROUND: Immunophenotypic modulation is induced by steroids in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients during remission induction therapy.
  • RESULTS: Leukemia samples that sustained the treatment in vitro with prednisone, showed significative reduction of CD10 and CD34 expression compared with control, and it was comparable with that observed in residual leukemic cells of the same patients in BM at day 15 of treatment.
  • [MeSH-major] Antigens, CD34 / metabolism. Neprilysin / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / drug effects. Precursor Cells, B-Lymphoid / immunology. Prednisone / pharmacology
  • [MeSH-minor] Adolescent. Cell Culture Techniques. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society
  • (PMID = 18271020.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  •  go-up   go-down


27. Xu JW, Jin RM, Li EQ, Wang YR, Bai Y: Signal pathways in ouabain-induced proliferation of leukemia cells. World J Pediatr; 2009 May;5(2):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal pathways in ouabain-induced proliferation of leukemia cells.
  • BACKGROUND: Cardiotonic steroids (CTSs) can bind to Na(+)/K(+)-ATPase and activate protein kinase cascades, resulting in changes in cell proliferation, differentiation or apoptosis in a cell-specific manner.
  • We explored the participation of ouabain-activated signaling pathways in growth regulation of leukemia cells.
  • METHODS: Lymphocytic leukemia Jhhan cells and megakaryocytic leukemia M07e cells were incubated at different concentrations of ouabain (0, 1 and 10 nmol) for 24 hours.
  • Cell proliferation was measured by methyl thiazolyl tetrazolium (MTT) assay.
  • To probe the role of ouabain-induced signaling in control of cell growth, we employed Src kinase inhibitor PP2 and the MEK inhibitor PD98059, respectively.
  • The expression of Na(+)/K(+)-ATPase alpha1 subunit of leukemia cells was evaluated by RT-PCR and Western blotting.
  • Addition of either PP2 or PD98059 blocked the effects of ouabain on cell proliferation.
  • CONCLUSION: Ouabain activates Src and ERK1/2 pathways and regulates the proliferation of leukemia cells.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Leukemia, Lymphoid / metabolism. Leukemia, Megakaryoblastic, Acute / metabolism. Ouabain / pharmacology. Signal Transduction / drug effects. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Humans. In Vitro Techniques. Sodium-Potassium-Exchanging ATPase / metabolism

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. OUABAIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63 [1648735.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 23):4223-32 [10564641.001]
  • [Cites] J Am Soc Nephrol. 2006 Jul;17(7):1848-57 [16707566.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3838-47 [10919658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10911-6 [16835298.001]
  • [Cites] J Intern Med. 2007 Jan;261(1):44-52 [17222167.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):274-5 [16421553.001]
  • [Cites] J Urol. 2001 Jul;166(1):347-53 [11435898.001]
  • [Cites] J Biol Chem. 1986 Feb 25;261(6):2860-5 [3005269.001]
  • [Cites] Life Sci. 2007 May 16;80(23):2093-107 [17499813.001]
  • [Cites] J Biol Chem. 1994 Aug 5;269(31):19659-62 [8051040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13420-4 [11687608.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1071-81 [15616198.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27838-44 [10874029.001]
  • [Cites] FEBS Lett. 2004 Apr 9;563(1-3):151-4 [15063740.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 18;534(1-3):71-6 [16507306.001]
  • [Cites] Arch Biochem Biophys. 1994 Apr;310(1):32-9 [8161218.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Aug;293(2):C509-36 [17494630.001]
  • [Cites] J Biol Chem. 2006 Jul 21;281(29):20085-94 [16714287.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Sep;227(8):561-9 [12192097.001]
  • [Cites] Eur J Biochem. 2002 May;269(10):2434-9 [12027880.001]
  • [Cites] Mol Interv. 2008 Feb;8(1):36-49 [18332483.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1768(7):1691-702 [17524349.001]
  • [Cites] Mol Biol Cell. 2006 Jan;17(1):317-26 [16267270.001]
  • [Cites] Am J Physiol. 1995 Aug;269(2 Pt 1):C295-311 [7653511.001]
  • (PMID = 19718538.001).
  • [ISSN] 1708-8569
  • [Journal-full-title] World journal of pediatrics : WJP
  • [ISO-abbreviation] World J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 5ACL011P69 / Ouabain; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


28. Finette BA: Analysis of mutagenic V(D)J recombinase mediated mutations at the HPRT locus as an in vivo model for studying rearrangements with leukemogenic potential in children. DNA Repair (Amst); 2006 Sep 8;5(9-10):1049-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric acute lymphocytic leukemia (ALL) is a multifactorial malignancy with many distinctive developmentally specific features that include age specific acquisition of deletions, insertions and chromosomal translocations.
  • In this review, I will present the utility of analyzing mutagenic V(D)J recombinase mediated genomic rearrangements at the HPRT locus in humans as an in vivo model system for understanding the mechanisms responsible for leukemogenic genetic alterations observed in children with leukemia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hypoxanthine Phosphoribosyltransferase / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic. VDJ Recombinases / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807138.001).
  • [ISSN] 1568-7864
  • [Journal-full-title] DNA repair
  • [ISO-abbreviation] DNA Repair (Amst.)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA09094013; United States / NCI NIH HHS / CA / CA094013; United States / NCI NIH HHS / CA / CA22435; United States / NCI NIH HHS / CA / CA77737; United States / NIEHS NIH HHS / ES / F32ES011693; United States / NICHD NIH HHS / HD / HD35309
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase; EC 2.7.7.- / VDJ Recombinases
  • [Number-of-references] 151
  •  go-up   go-down


29. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, Vora A, Mitchell CD, Harrison CJ: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol; 2010 May;11(5):429-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
  • BACKGROUND: Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes.
  • METHODS: We analysed cytogenetic data from 1725 children with B-cell precursor acute lymphoblastic leukaemia who were included in the UK Medical Research Council ALL97/99 study and followed up for a median time of 8.2 years.
  • Multivariate analysis incorporating age, white-cell count, and treatment parameters showed that six cytogenetic abnormalities (ETV6-RUNX1, high hyperdiploidy, iAMP21, t(9;22), loss of 13q, and abnormal 17p) retained their significance for effect on relapse risk.
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 May;11(5):403-4 [20409755.001]
  • [ErratumIn] Lancet Oncol. 2010 Jun;11(6):516
  • (PMID = 20409752.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Yetgin S, Kuskonmaz B, Aytaç S, Tavil B: An unusual case of reactive lymphocytosis mimicking acute leukemia. Pediatr Hematol Oncol; 2007 Mar;24(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of reactive lymphocytosis mimicking acute leukemia.
  • The diagnosis of acute leukemia is based on a combination of clinical, hematological, morphological, cytogenetic, and immunophenotypic data.
  • The authors report a case of reactive lymphocytosis with extremely elevated lymphocytic and lymphoblastic leukocytosis that mimicked acute lymphoblastic leukemia, not only morphologically, but also in immunophenotypic analysis.
  • Although this case presented with extremely high lymphocytic leukocytosis, the patient had normal blood cell lineage, a moderate level of blastic cells in bone marrow, and normal physical findings.
  • [MeSH-major] Lymphocytosis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454779.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Miller AL, Komak S, Webb MS, Leiter EH, Thompson EB: Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids. Cancer Cell Int; 2007 Nov 28;7:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric CD4+/CD8+ T-cell leukemia was represented by 3 CEM clones: two sensitive, CEM-C7-14 and CEM-C1-6, and one resistant, CEM-C1-15, to Dex.
  • GC-sensitive pediatric B-cell leukemia was represented by the SUP-B15 line and adult B-cell leukemia by RS4;11 cells.
  • Kasumi-1 cells gave an example of the rare Dex-sensitive acute myeloblastic leukemia (AML).
  • To test the generality of the correlations in malignant cell gene sets, we compared with GC effects on mouse non-transformed thymocytes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Growth Differ. 1995 May;6(5):505-13 [7647033.001]
  • [Cites] Leuk Res. 1997 Jan;21(1):45-50 [9029185.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3684-93 [9721879.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2730-41 [9763557.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1807-17 [9885901.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]
  • [Cites] Cell Death Differ. 1999 Dec;6(12):1182-9 [10637434.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4324-36 [11466613.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1346-58 [11857078.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2283-93 [11884613.001]
  • [Cites] Neoplasia. 2002 Jan-Feb;4(1):68-81 [11922393.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 17;293(4):1254-61 [12054511.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):277-84 [12519866.001]
  • [Cites] Leukemia. 2003 Jan;17(1):17-25 [12529655.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):23861-7 [12676946.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27053-8 [12736248.001]
  • [Cites] Genomics. 2003 Jun;81(6):543-55 [12782123.001]
  • [Cites] Recent Prog Horm Res. 2003;58:175-97 [12795419.001]
  • [Cites] Cancer. 1965 Apr;18:522-9 [14278051.001]
  • [Cites] Eur J Endocrinol. 2004 Jan;150(1):41-7 [14713278.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20858-65 [14996839.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):49-55 [15130510.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55809-17 [15509554.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2519-26 [15572593.001]
  • [Cites] Ann Acad Med Singapore. 2004 Sep;33(5 Suppl):S21-2 [15651190.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6050-6 [16115950.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4131-8 [16118324.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2061-9 [16293608.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1903-13 [16301999.001]
  • [Cites] Leukemia. 2006 Jun;20(6):987-93 [16598301.001]
  • [Cites] FEBS Lett. 2006 Jun 12;580(14):3539-44 [16730715.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Nov;319(2):887-97 [16914556.001]
  • [Cites] J Dermatol. 2006 Oct;33(10):662-9 [17040494.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39051-61 [17062574.001]
  • [Cites] Leukemia. 2007 Feb;21(2):281-7 [17151701.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Ann Rheum Dis. 2007 Oct;66(10):1289-95 [17267514.001]
  • [Cites] Cancer Cell Int. 2007;7:3 [17391526.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4482-90 [17483364.001]
  • [Cites] Steroids. 2007 Sep;72(9-10):673-81 [17606285.001]
  • [Cites] Blood. 1991 May 1;77(9):2031-6 [2018839.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991 May;38(5):561-8 [2039752.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2876-9 [3162827.001]
  • [Cites] Blood. 1985 Jan;65(1):21-31 [3917311.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):241-6 [3926660.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1771-8 [7564524.001]
  • (PMID = 18045478.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA041407
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2228275
  •  go-up   go-down


32. Baris S, Celkan T, Batar B, Guven M, Ozdil M, Ozkan A, Apak H, Yildiz I: Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol; 2009 Sep;26(6):467-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma.
  • OBJECTIVES: The authors evaluated the possible effect of DNA repair genes, XPD (Xeroderma pigmentosum group D) codon (312 and 751) and XRCC1 (X-ray repair cross-complementing group 1) codon (194 and 399) SNPs (single-nucleotide polymorphisms) on the risk of childhood B-cell lymphoma.
  • RESULTS: The authors observed no association between variation in the XPD codon Asp312Asn, Lys751Gln, and XRCC1 codon Arg399Gln polymorphisms and B-cell lymphoma for any parameter.
  • The frequency of XRCC1 194Arg/Trp genotype in B-cell lymphoma was significantly lower than that in controls (p = .005).
  • CONCLUSIONS: XRCC1 194Trp allele may be associated with a protective effect against development of childhood B-cell lymphoma.
  • [MeSH-major] DNA Repair / genetics. DNA-Binding Proteins / genetics. Lymphoma, B-Cell / genetics. Polymorphism, Single Nucleotide / genetics. Xeroderma Pigmentosum Group D Protein / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19657998.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein
  •  go-up   go-down


33. Reddy H, Jamil K: Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in an Indian population. Leuk Lymphoma; 2006 Jul;47(7):1333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the MTHFR gene and their possible association with susceptibility to childhood acute lymphocytic leukemia in an Indian population.
  • Acute lymphocytic leukemia (ALL) is the most common pediatric cancer worldwide, and is particularly more common in the Indian population.
  • [MeSH-major] Genetic Predisposition to Disease. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Jul;47(7):1203-4 [16923547.001]
  • (PMID = 16923565.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


34. Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ: Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. Genet Vaccines Ther; 2005 Jun 21;3(1):4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines.
  • BACKGROUND: The production of cell-based cancer vaccines by gene vectors encoding proteins that stimulate the immune system has advanced rapidly in model systems.
  • We sought to develop non-viral transfection methods that could transform patient tumor cells into cancer vaccines, paving the way for rapid production of autologous cell-based vaccines.
  • METHODS: As the extended culture and expansion of most patient tumor cells is not possible, we sought to first evaluate a new technology that combines electroporation and chemical transfection in order to determine if plasmid-based gene vectors could be instantaneously delivered to the nucleus, and to determine if gene expression was possible in a cell-cycle independent manner.
  • We tested cultured cell lines, a primary murine tumor, and primary human leukemia cells from diagnostic work-up for transgene expression, using both RFP and CD137L expression vectors.
  • However, the kinetics of gene expression from plasmid-based vectors in tumor cell lines indicated that optimal gene expression was still dependent on cell division.
  • We then tested to see if pediatric acute lymphocytic leukemia (ALL) would also display the rapid gene expression kinetics of tumor cells lines, determining gene expression 24 hours after transfection.
  • CONCLUSION: Given that transgene expression could be detected in a majority of primary tumor samples analyzed within hours, direct electroporation-based transfection of primary leukemia holds the potential to generate patient-specific cancer vaccines.
  • Plasmid-based gene therapy represents a simple means to generate cell-based cancer vaccines and does not require the extensive infrastructure of a virus-based vector system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Enzymol. 1995;254:125-33 [8531681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13141-6 [9789055.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1340-5 [10455446.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):83-7 [11753367.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):396-400 [15531579.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1718-26 [12406881.001]
  • [Cites] Cell Immunol. 2003 Mar;222(1):15-26 [12798304.001]
  • [Cites] Exp Cell Res. 2004 Oct 1;299(2):267-78 [15350526.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):681-9 [15522656.001]
  • [Cites] Mol Ther. 2002 Jan;5(1):80-6 [11786049.001]
  • (PMID = 15969754.001).
  • [ISSN] 1479-0556
  • [Journal-full-title] Genetic vaccines and therapy
  • [ISO-abbreviation] Genet Vaccines Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182385
  •  go-up   go-down


35. Hanna-Wakim R, Yasukawa LL, Sung P, Fang M, Sullivan B, Rinki M, DeHovitz R, Arvin AM, Gans HA: Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis; 2009 Dec 15;200(12):1921-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood.
  • Immune maturation is complex, however, and the interval during which changes occur during childhood has not been identified.
  • METHODS: To assess age-related differences in the CD4(+) T cell responses, we evaluated the frequency of CD4(+) T cells that produced interferon (IFN) gamma in response to staphylococcal enterotoxin B (SEB) stimulation in 382 healthy infants and children (2 months to 11 years of age) and 66 adults.
  • Observed differences in CD45RO(+)CD4(+) T cell function indicate that CD4(+) T cells with the same phenotypes do not possess equivalent functional capabilities.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19909079.001).
  • [ISSN] 1537-6613
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI37127
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / CD69 antigen; 0 / Enterotoxins; 0 / Lectins, C-Type; 147205-72-9 / CD40 Ligand; 39424-53-8 / enterotoxin B, staphylococcal; 82115-62-6 / Interferon-gamma; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


36. Kouros CD, Cummings EM, Davies PT: Early trajectories of interparental conflict and externalizing problems as predictors of social competence in preadolescence. Dev Psychopathol; 2010 Aug;22(3):527-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Consistent with developmental cascade notions, the present study investigated (a) associations between trajectories of interparental conflict and early externalizing problems during childhood and (b) early trajectories of externalizing problems as a pathway by which interparental conflict impacts children's social competence in preadolescence.
  • Results from parallel process models indicated that changes in interparental conflict were positively associated with changes in externalizing problems during childhood.

  • MedlinePlus Health Information. consumer health - Child Behavior Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Child Dev. 1999 Nov-Dec;70(6):1373-400 [10621962.001]
  • [Cites] J Pers. 2000 Dec;68(6):1109-26 [11130734.001]
  • [Cites] J Child Psychol Psychiatry. 2001 Jul;42(5):679-89 [11464972.001]
  • [Cites] Child Dev. 2003 Jul-Aug;74(4):1176-93 [12938712.001]
  • [Cites] J Fam Psychol. 2004 Mar;18(1):160-70 [14992618.001]
  • [Cites] J Abnorm Child Psychol. 2004 Apr;32(2):191-202 [15164860.001]
  • [Cites] J Abnorm Child Psychol. 2004 Aug;32(4):409-23 [15305546.001]
  • [Cites] J Abnorm Child Psychol. 1988 Apr;16(2):197-206 [3385083.001]
  • [Cites] Child Dev. 1991 Dec;62(6):1424-33 [1786725.001]
  • [Cites] J Consult Clin Psychol. 1992 Oct;60(5):783-92 [1401394.001]
  • [Cites] Psychol Bull. 1993 Jan;113(1):99-128 [8426876.001]
  • [Cites] Psychol Rev. 1993 Oct;100(4):674-701 [8255953.001]
  • [Cites] J Abnorm Child Psychol. 1994 Apr;22(2):147-66 [8064027.001]
  • [Cites] Child Dev. 1996 Jun;67(3):1103-18 [8706512.001]
  • [Cites] Child Dev. 1997 Apr;68(2):333-50 [9180005.001]
  • [Cites] Dev Psychopathol. 1997 Spring;9(2):251-68 [9201444.001]
  • [Cites] Dev Psychol. 1997 Jul;33(4):657-68 [9232381.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Jul;38(5):581-6 [9255702.001]
  • [Cites] J Clin Child Psychol. 1997 Dec;26(4):415-23 [9418180.001]
  • [Cites] Child Dev. 2006 Jan-Feb;77(1):132-52 [16460530.001]
  • [Cites] J Fam Psychol. 2006 Mar;20(1):30-9 [16569087.001]
  • [Cites] Child Dev. 2007 May-Jun;78(3):775-89 [17517004.001]
  • [Cites] Adolescence. 2007 Spring;42(165):115-36 [17536478.001]
  • [Cites] J Abnorm Child Psychol. 2007 Oct;35(5):831-43 [17534712.001]
  • [Cites] J Fam Psychol. 2007 Sep;21(3):416-25 [17874927.001]
  • [Cites] J Stud Alcohol Drugs. 2008 Jan;69(1):100-11 [18080070.001]
  • [Cites] J Fam Psychol. 2007 Dec;21(4):614-25 [18179333.001]
  • [Cites] Dev Psychopathol. 2008 Winter;20(1):195-212 [18211734.001]
  • [Cites] J Consult Clin Psychol. 2008 Feb;76(1):138-48 [18229991.001]
  • [Cites] Child Dev. 2008 Mar-Apr;79(2):359-74 [18366428.001]
  • [Cites] Dev Sci. 2008 May;11(3):F9-16 [18466367.001]
  • [Cites] J Abnorm Psychol. 2008 May;117(2):289-99 [18489205.001]
  • [Cites] Psychol Med. 2008 Jul;38(7):989-99 [18047767.001]
  • [Cites] J Fam Psychol. 2008 Oct;22(5):667-77 [18855503.001]
  • [Cites] Infant Behav Dev. 2009 Jan;32(1):91-102 [19095308.001]
  • [Cites] Emotion. 2009 Feb;9(1):15-28 [19186913.001]
  • [Cites] Psychol Addict Behav. 2009 Mar;23(1):36-46 [19290688.001]
  • [Cites] Monogr Soc Res Child Dev. 2009;74(1):vii, 1-79 [19302676.001]
  • [Cites] J Child Psychol Psychiatry. 2009 Mar;50(3):270-9 [18673403.001]
  • [Cites] J Fam Psychol. 2009 Apr;23(2):130-45 [19364208.001]
  • [Cites] Dev Psychopathol. 1999 Winter;11(1):59-84 [10208356.001]
  • [Cites] Dev Psychol. 1999 Sep;35(5):1283-96 [10493654.001]
  • [Cites] Dev Psychol. 2005 Sep;41(5):733-46 [16173871.001]
  • [Cites] Dev Psychol. 2005 Sep;41(5):812-23 [16173877.001]
  • (PMID = 20576176.001).
  • [ISSN] 1469-2198
  • [Journal-full-title] Development and psychopathology
  • [ISO-abbreviation] Dev. Psychopathol.
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / T32-MH18921; United States / NIMH NIH HHS / MH / T32 MH018921; United States / NIMH NIH HHS / MH / T32 MH018921-20S1; United States / NIMH NIH HHS / MH / MH057318-01A2; United States / NIMH NIH HHS / MH / R01 MH057318-01A2; United States / NIMH NIH HHS / MH / MH018921-20S1; United States / NIMH NIH HHS / MH / R01 MH057318-06; United States / NIMH NIH HHS / MH / R01 MH057318; United States / NIMH NIH HHS / MH / R01 MH57318
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS220333; NLM/ PMC2911621
  •  go-up   go-down


37. Sudhakar N, Nirmala K, Rajalekshmy KR, Rajkumar T: Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients? Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does TAL-1 deletion contribute to the high incidence of T-cell acute lymphoblastic leukemia in South Indian patients?
  • BACKGROUND: The incidence of T-cell acute lymphoblastic leukemia (T-ALL) in South India is very high (43.1%) when compared to the Western countries (10-20%).
  • MATERIALS AND METHODS: 45 cases of T-ALL (pediatric-32, adolescents-7 and young adults-6) were studied by DNA-PCR and sequencing.
  • RESULTS: TAL-1 deletion type 1 was detected in 6 (13.3%) cases (3 pediatric and 3 adolescents) and all were males.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439091.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


38. Sehgal S, Mujtaba S, Gupta D, Aggarwal R, Marwaha RK: High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: a preliminary study. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):63-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of Epstein Barr virus infection in childhood acute lymphocytic leukemia: a preliminary study.
  • OBJECTIVE: The study aims to investigate the association of EBV in childhood leukemia.
  • MATERIAL AND METHODS: Patients attending pediatric oncology services of the referral center have been included in the study.
  • Twenty-five consecutive pediatric patients with acute lymphocytic lukemia (ALL) were subjected to EBV studies employing sensitive polymerase chain reaction followed by hybridization for presence of Bam H1-W region of EBV genome and detection of anti Z EBV replication activator (ZEBRA) antibodies using Western blot.
  • [MeSH-major] Epstein-Barr Virus Infections / epidemiology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):890-1 [21045472.001]
  • (PMID = 20090225.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral
  •  go-up   go-down


39. Olsen M, Madsen HO, Hjalgrim H, Gregers J, Rostgaard K, Schmiegelow K: Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood. J Pediatr Hematol Oncol; 2006 Nov;28(11):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood.
  • The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cell precursor acute lymphoblastic leukemia (ALL), where it occurs in 25% of all cases.
  • Evidence suggests that the TEL-AML1 translocation occurs in utero in 1% of all newborn children at cell levels of 10 to 10.
  • The observed prevalence of TEL-AML1-positive cells in healthy adults is of the same order of magnitude as the prevalence reported in healthy newborns, but the observed cell level of 10 to 10 is much lower.
  • These data indicates that prenatal TEL-AML1 subclones does not persist throughout adult life at cell levels of 10 to 10.
  • The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-positive cells in peripheral blood in both childhood and adulthood.
  • [MeSH-minor] Adult. Blood Donors. Child. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114960.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


40. Liu Y, Tang JY, Xu C, Gu LJ, Xue HL, Chen J, Pan C, Dong L, Zhou M: [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2009 May;47(5):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
  • OBJECTIVE: To probe into the occurrence rates of the effective antigen combinations which were used to detect the minimal residual disease (MRD) by flow cytometry in childhood B-lineage acute lymphoblastic leukemia (B-ALL), as well as the relationship between clinical-biologic factors and different combinations.
  • (1) Totally 327 cases of childhood B-ALL were screened for antibody combinations of interest and 88.4 percent of them (289 cases) were identified with effective antibody combinations. (2) The occurrence frequencies of antigen combinations were different.
  • [MeSH-major] Leukemia, B-Cell / immunology. Leukemia, B-Cell / therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy


41. Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A, Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy. Br J Haematol; 2010 Apr;149(1):93-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
  • The presence of a dicentric chromosome dic(9;20) has been reported to have an unfavourable prognosis in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067563.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


42. Ritch CR, Poon SA, Sulis ML, Schlussel RN: Cutaneous vesicostomy for palliative management of hemorrhagic cystitis and urinary clot retention. Urology; 2010 Jul;76(1):166-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 9 year old boy with hemorrhagic cystitis and urinary clot retention in the setting of chemotherapy refractory pre-B cell acute lymphocytic leukemia.

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20394973.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK: Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood; 2009 Sep 24;114(13):2678-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 80%.
  • Here, we report ectopic expression of the receptor tyrosine kinase Mer in pediatric B-cell ALL.
  • Inhibition of Mer prevented Erk 1/2 activation, increased the sensitivity of B-ALL cells to cytotoxic agents in vitro by promoting apoptosis, and delayed disease onset in a mouse model of leukemia.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2008 Jan 1;111(1):379-82 [17878402.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008;22(4):519-25 [18228243.001]
  • [Cites] Biotechnol Bioeng. 2008 Apr 15;99(6):1443-52 [18023050.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] Cancer Lett. 2008 Sep 18;268(2):314-24 [18502572.001]
  • [Cites] Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21 [18760705.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3038-50 [18704194.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7409-18 [18794129.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):177-81 [18816698.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):7971-4 [19088011.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2142-50 [18818707.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1687-95 [10738228.001]
  • [Cites] Cancer Treat Rev. 2001 Dec;27(6):351-63 [11908928.001]
  • [Cites] Methods. 2002 Jan;26(1):57-75 [12054905.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24057-66 [11929866.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):23977-80 [11997383.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1071-8 [12168903.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):601-3 [15295054.001]
  • [Cites] Nature. 1977 Jun 30;267(5614):841-3 [197411.001]
  • [Cites] Blood. 1984 Mar;63(3):721-4 [6607758.001]
  • [Cites] Blood. 1990 Jul 1;76(1):117-22 [2364165.001]
  • [Cites] J Clin Oncol. 1990 Aug;8(8):1380-8 [2380759.001]
  • [Cites] Blood. 1991 Feb 15;77(4):687-93 [1671560.001]
  • [Cites] Leukemia. 1991 Apr;5(4):322-31 [2027299.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1865-74 [8231254.001]
  • [Cites] Cell Growth Differ. 1994 Jun;5(6):647-57 [8086340.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6582-92 [8524223.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1211-24 [8608207.001]
  • [Cites] EMBO J. 1996 Dec 2;15(23):6541-51 [8978681.001]
  • [Cites] Oncogene. 1997 May 1;14(17):2033-9 [9160883.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4442-53 [9234702.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1171-81 [9891051.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1352-8 [10482985.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1058-64 [16354588.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2662-9 [16675557.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6092-100 [16652142.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1026-33 [17047157.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):545-53 [17379584.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5473-6 [17351113.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Brain Res. 2007 Jul 16;1158:39-49 [17559813.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2074-81 [17716890.001]
  • [RetractionIn] Blood. 2012 Aug 16;120(7):1533 [22753864.001]
  • (PMID = 19643988.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / F32 HL096416; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NHLBI NIH HHS / HL / F32HL096416; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; EC 2.7.10.1 / MERTK protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC2927045
  •  go-up   go-down


44. Volbrecht MM, Goldsmith HH: Early temperamental and family predictors of shyness and anxiety. Dev Psychol; 2010 Sep;46(5):1192-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using hierarchical linear modeling with restricted maximum likelihood estimation to adjust for twin dependency, early BI (b = 0.37, p < .01), IC (b = 0.14, p < .05), and concurrent lower family stress (b = -0.22, p < .05) predicted shyness during middle childhood.
  • Anxiety symptoms were predicted by BI (b = 0.14, p < .05), early negative family affect (b = 0.20, p < .05), and family stress in middle childhood (b = 0.26, p < .05).
  • These findings clarify the relative importance of temperament and family factors in the development of both shyness and anxiety symptoms during childhood.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Psychiatry. 2008 Nov;165(11):1449-55 [18708488.001]
  • [Cites] Dev Psychol. 2008 Sep;44(5):1354-68 [18793068.001]
  • [Cites] J Child Psychol Psychiatry. 2008 Dec;49(12):1257-69 [18355216.001]
  • [Cites] Am J Psychiatry. 2010 Jan;167(1):40-6 [19917594.001]
  • [Cites] J Child Psychol Psychiatry. 2011 May;52(5):607-18 [21198591.001]
  • [Cites] Biol Psychiatry. 1999 Dec 1;46(11):1536-41 [10599481.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):461-8 [10761348.001]
  • [Cites] Clin Psychol Rev. 2000 Jun;20(4):453-78 [10832549.001]
  • [Cites] J Clin Child Psychol. 2000 Sep;29(3):328-35 [10969417.001]
  • [Cites] Am J Psychiatry. 2001 Oct;158(10):1568-78 [11578982.001]
  • [Cites] Am J Psychiatry. 2001 Oct;158(10):1673-9 [11579001.001]
  • [Cites] Child Dev. 2001 Sep-Oct;72(5):1394-408 [11699677.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2002 Apr;41(4):458-66 [11931603.001]
  • [Cites] Twin Res. 2002 Apr;5(2):125-31 [11931690.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 2002 May;41(5):588-603 [12014792.001]
  • [Cites] J Child Psychol Psychiatry. 2002 May;43(4):457-69 [12030592.001]
  • [Cites] Child Dev. 2002 May-Jun;73(3):935-51 [12038561.001]
  • [Cites] Child Dev. 2002 Sep-Oct;73(5):1474-85 [12361313.001]
  • [Cites] Child Dev. 2003 May-Jun;74(3):933-43 [12795399.001]
  • [Cites] J Child Psychol Psychiatry. 2003 Oct;44(7):945-60 [14531577.001]
  • [Cites] J Child Psychol Psychiatry. 2003 Nov;44(8):1092-115 [14626453.001]
  • [Cites] Am J Psychiatry. 2003 Dec;160(12):2116-21 [14638580.001]
  • [Cites] J Clin Child Adolesc Psychol. 2004 Mar;33(1):82-7 [15028543.001]
  • [Cites] Dev Psychol. 2004 May;40(3):367-77 [15122963.001]
  • [Cites] Child Dev. 2004 Sep-Oct;75(5):1477-90 [15369526.001]
  • [Cites] J Consult Clin Psychol. 1978 Oct;46(5):932-46 [701572.001]
  • [Cites] Child Dev. 1987 Apr;58(2):505-29 [3829791.001]
  • [Cites] Child Dev. 1989 Aug;60(4):838-45 [2758880.001]
  • [Cites] J Child Psychol Psychiatry. 1992 Sep;33(6):977-85 [1400693.001]
  • [Cites] J Child Psychol Psychiatry. 1993 Sep;34(6):851-67 [8408371.001]
  • [Cites] J Child Psychol Psychiatry. 1995 Mar;36(3):439-47 [7782407.001]
  • [Cites] J Abnorm Psychol. 1995 Aug;104(3):526-31 [7673576.001]
  • [Cites] Child Dev. 1996 Apr;67(2):490-507 [8625724.001]
  • [Cites] Arch Gen Psychiatry. 1996 Nov;53(11):1033-9 [8911226.001]
  • [Cites] Behav Genet. 1997 Jan;27(1):15-28 [9145540.001]
  • [Cites] J Child Psychol Psychiatry. 1997 Nov;38(8):965-80 [9413795.001]
  • [Cites] Am Psychol. 1998 Feb;53(2):185-204 [9491747.001]
  • [Cites] Am Psychol. 1998 Feb;53(2):221-41 [9491749.001]
  • [Cites] Dev Psychopathol. 1998 Winter;10(1):39-59 [9524807.001]
  • [Cites] J Nerv Ment Dis. 1998 Jul;186(7):425-31 [9680044.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):1008-15 [10434493.001]
  • [Cites] Dev Psychol. 2005 Jan;41(1):193-211 [15656749.001]
  • [Cites] Annu Rev Psychol. 2005;56:235-62 [15709935.001]
  • [Cites] J Consult Clin Psychol. 2005 Jun;73(3):488-97 [15982146.001]
  • [Cites] Psychol Sci. 2005 Aug;16(8):609-16 [16102063.001]
  • [Cites] Psychol Bull. 2006 Jan;132(1):33-72 [16435957.001]
  • [Cites] Dev Psychopathol. 1999 Spring;11(2):209-24 [16506531.001]
  • [Cites] Dev Psychopathol. 2006 Spring;18(2):517-50 [16600066.001]
  • [Cites] Clin Psychol Rev. 2006 Nov;26(7):834-56 [16473441.001]
  • [Cites] Soc Sci Med. 2006 Nov;63(10):2546-61 [16914244.001]
  • [Cites] Clin Psychol Rev. 2007 Mar;27(2):155-72 [17112647.001]
  • [Cites] Twin Res Hum Genet. 2006 Dec;9(6):1030-7 [17254447.001]
  • [Cites] Monogr Soc Res Child Dev. 2007;72(2):1-75, vii; discussion 76-91 [17661895.001]
  • [Cites] Clin Child Fam Psychol Rev. 2007 Sep;10(3):199-212 [17503180.001]
  • [Cites] Dev Psychol. 2008 Mar;44(2):316-29 [18331125.001]
  • [Cites] J Abnorm Child Psychol. 2008 Apr;36(3):359-71 [17899358.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258(2):69-75 [18297422.001]
  • [Cites] Annu Rev Clin Psychol. 2008;4:275-303 [18370618.001]
  • [Cites] Dev Psychol. 2008 Jul;44(4):997-1011 [18605830.001]
  • [Cites] Annu Rev Psychol. 2009;60:141-71 [18851686.001]
  • (PMID = 20822232.001).
  • [ISSN] 1939-0599
  • [Journal-full-title] Developmental psychology
  • [ISO-abbreviation] Dev Psychol
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH050560-08; United States / NIMH NIH HHS / MH / P50 MH084051; United States / NIMH NIH HHS / MH / R37 MH050560-08; United States / NIMH NIH HHS / MH / R01 MH059785-01A1; United States / NIMH NIH HHS / MH / P50 MH069315-01; None / None / / P50 MH069315-01; United States / NIMH NIH HHS / MH / R01 MH059785; United States / NIMH NIH HHS / MH / R37 MH050560; United States / NIMH NIH HHS / MH / P50 MH069315; United States / NIMH NIH HHS / MH / MH059785-01A1
  • [Publication-type] Journal Article; Twin Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS283658; NLM/ PMC3086562
  •  go-up   go-down


45. Lawce H, Olson S: FISH testing for deletions of chromosome 6q21 and 6q23 in hematologic neoplastic disorders. J Assoc Genet Technol; 2009;35(4):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosome 6q deletions are also commonly found in lymphoid malignancies such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), multiple myeloma (MM), mantle zone lymphoma (MZL), and Waldenström's macroglobulinemia (WM).
  • In childhood B- and T-cell ALL a deletion of 6q is the hallmark of a neutral prognosis; however, it may be cytogenetically obscure or cryptic, requiring interphase FISH analysis.
  • In adult ALL it indicates a favorable prognosis, but in CLL, B-cell small lymphocytic lymphoma (SLL), WM, and MM it has a poor prognosis.
  • We report the results of the first three patients in our laboratory with deletions of 6q in lymphoid malignancies using this cocktail.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952391.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. He GS, Zhang XH, Yao L, Zhang R, Chen ZX, Wu DP, Sun AN, Jin ZM, Qiu HY, Hu XH: [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):675-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
  • OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).
  • The leukemic cells expressed T cell markers.
  • CONCLUSION: t(1;19)E2A-PBX1(+) can be implicated in adult T-ALL, besides childhood B-ALL.
  • [MeSH-major] Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954663.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


47. Holland-Cunz S, Göppl M, Rauch U, Bär C, Klotz M, Schäfer KH: Acquired intestinal aganglionosis after a lytic infection with varicella-zoster virus. J Pediatr Surg; 2006 Mar;41(3):e29-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 3-year-old girl with acute lymphoblastic leukemia and generalized varicella-zoster infection developed an ileus.
  • A more detailed immunohistochemical analysis using neuronal (PGP, enolase), glial (S100), and lymphocytic (LCA) antibodies demonstrated a nearly complete neuronal loss.
  • [MeSH-minor] Child, Preschool. Female. Humans. Ileus / etiology. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516611.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Gobbi G, Mirandola P, Malinverno C, Sponzilli I, Carubbi C, Ricci F, Binazzi R, Basso G, Giuliani-Piccari G, Ramazzotti G, Pasquantonio G, Cocco L, Vitale M: Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin. Int J Oncol; 2008 Aug;33(2):371-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin.
  • The B203.13 monoclonal antibody was developed by immunizing mice with the B/monocyte biphenotypic cell line B1b.
  • We tested this antibody as a marker of childhood B-acute lymphoblastic leukemia (B-ALL).
  • The CD10(+)/B203.13(+) phenotype was specific to B-ALL, since CD10(+)/CD20(+) cells from common acute lymphoblastic leukemia (c-ALL) did not express B203.13.
  • We concluded that the use of B203.13 in association with CD10 and CD20 provides meaningful information for distinguishing normal residual B-cells from leukemic B-lymphoblasts and that recurrence of a CD10(+)/B203.13(+) phenotype after transplantation may be a very early relapse indicator of early B-acute lymphoblastic leukemia.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636158.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, Neoplasm; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


49. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M: Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia; 2006 Feb;20(2):254-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
  • Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia.
  • We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear.
  • Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM).
  • In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM.
  • WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (P<0.001).
  • In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL.
  • WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL.
  • Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Molecular Diagnostic Techniques / methods. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / genetics


50. Xu C, Zhao HJ, Jiang LM, Yuan XJ, Li L, Tang JY, Shen LS: [Prognostic significance of lymphocyte function associated anti-gen-3 (CD58) in childhood B cell-acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):717-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic significance of lymphocyte function associated anti-gen-3 (CD58) in childhood B cell-acute lymphocytic leukemia].
  • This study was aimed to investigate the value of CD58 in evaluation of early therapeutic effect on childhood B-ALL.
  • The expression features of CD58 in 135 cases of childhood B-ALL were analyzed by four-color flow cytometry; MRD detection protocol for B-ALL using CD58/CD10/CD34/CD19 combination was established; the correlation between the expression features of CD58 and MRD detection was analyzed for the early therapeutic response in childhood B-ALL.
  • The CD58 over expression may be considered as a marker of a favorable prognosis in childhood B-ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928307.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD58; 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des; 2009;15(23):2652-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No agents of this class are approved yet for medical use, although a related molecule, denileukin diftitox, composed of interleukin-2 fused to truncated diphtheria toxin, is approved for relapsed/refractory cutaneous T-cell lymphoma.
  • Major responses were observed with LMB-2 in adult T-cell leukemia, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, Hodgkin's disease, and hairy cell leukemia (HCL).
  • HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689336.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunotoxins; 0 / Leukocidins; 0 / Pseudomonas aeruginosa Cytotoxins; 0 / Recombinant Proteins; 0 / Toxins, Biological
  • [Number-of-references] 190
  •  go-up   go-down


52. Haltrich I, Csóka M, Kovács G, Fekete G: [Intrachromosomal amplification of AML1 gene in childhood acute lymphoblastic leukemia]. Orv Hetil; 2008 Jun 15;149(24):1143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrachromosomal amplification of AML1 gene in childhood acute lymphoblastic leukemia].
  • [Transliterated title] AML1-gén intrakromoszomális amplifikációja gyermekkori acut lymphoid leukaemiában.
  • The introduction of routine molecular cytogenetic assays enabled us to reveal hitherto unknown genetic disorders of childhood acute leukemias.
  • In our present study we review a novel cytogenetic mutation typical for childhood B-cell ALL, the intrachromosomal amplification of chromosome 21, which requires high-risk therapy irrespective of other risk factors, and which is associated with a cryptic 12;21 translocation of good prognostic value.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Gene Amplification. Genetic Markers. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18539581.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Genetic Markers; 0 / RUNX1 protein, human
  •  go-up   go-down


53. Campbell LK, Scaduto M, Van Slyke D, Niarhos F, Whitlock JA, Compas BE: Executive function, coping, and behavior in survivors of childhood acute lymphocytic leukemia. J Pediatr Psychol; 2009 Apr;34(3):317-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Executive function, coping, and behavior in survivors of childhood acute lymphocytic leukemia.
  • OBJECTIVE: To examine the role of executive function in coping and behavioral outcomes in childhood acute lymphocytic leukemia (ALL) survivors.
  • Directions for future research on executive function deficits and coping skills in survivors of pediatric ALL are suggested.
  • [MeSH-major] Adaptation, Psychological. Cognition. Emotions. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Stress, Psychological / etiology. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 May-Jun;22(3):206-13 [10864051.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • [Cites] J Pediatr Psychol. 2001 Jan-Feb;26(1):1-9 [11145727.001]
  • [Cites] Psychol Bull. 2001 Jan;127(1):87-127 [11271757.001]
  • [Cites] Psychosom Med. 2002 Jan-Feb;64(1):34-42 [11818584.001]
  • [Cites] J Pediatr Psychol. 2002 Apr-May;27(3):215-26 [11909929.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4395-401 [14645430.001]
  • [Cites] J Pers Soc Psychol. 1986 Dec;51(6):1173-82 [3806354.001]
  • [Cites] Pediatr Rehabil. 1997 Apr-Jun;1(2):63-76 [9689241.001]
  • [Cites] Arch Neurol. 1998 Dec;55(12):1561-8 [9865801.001]
  • [Cites] Pediatrics. 1999 Jan;103(1):71-8 [9917442.001]
  • [Cites] Neuroreport. 1999 Sep 9;10(13):2817-21 [10511446.001]
  • [Cites] Brain. 2006 Feb;129(Pt 2):333-45 [16364957.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):941-9 [16411228.001]
  • [Cites] Psychooncology. 2006 Jul;15(7):553-66 [16355435.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3858-64 [16921038.001]
  • [Cites] Annu Rev Psychol. 2007;58:119-44 [16903804.001]
  • [Cites] J Consult Clin Psychol. 2006 Dec;74(6):1132-42 [17154742.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1094:226-34 [17347354.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):65-73 [16628558.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3649-56 [17704415.001]
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1055-66 [17698880.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] J Consult Clin Psychol. 2000 Dec;68(6):976-92 [11142550.001]
  • (PMID = 18667478.001).
  • [ISSN] 1465-735X
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2722127
  •  go-up   go-down


54. Soliman Oel-S, Abd El-Aal Hegazi Hasan M, El-Ashry R, Zaghloul MH, Kora B: Parvovirus B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic parameters compared with nested PCR. J Pediatr Hematol Oncol; 2009 Mar;31(3):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parvovirus B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic parameters compared with nested PCR.
  • AIM: This study was designed to assess the prevalence and impact of parvovirus B19 in pediatric oncology patients receiving chemotherapy, and to define the optimal diagnostic tests in such patients.
  • SUBJECTS AND METHODS: Fifty-nine children under chemotherapy (39 with acute lymphocytic leukemia and 20 with solid tumors) with mean age of 4.96+/-1.94 years, in addition to 30 healthy children of matched age and sex, were enrolled in this study.
  • PCR-positive patients had significantly higher frequency of unexplained anemia, red blood cell transfusions, and longer hospital stay than PCR-negative patients (P<0.001).
  • Multiple linear regression analysis showed that unexplained anemia and multiple red blood cell transfusions were the most important variables that can predict PCR positivity.
  • CONCLUSIONS: Parvovirus B19 is not an uncommon problem in pediatric oncology patients who exhibited weak antibody response and nonspecific clinical features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262242.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antineoplastic Agents; 0 / DNA, Viral
  •  go-up   go-down


55. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T: Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med (Berl); 2010 Mar;88(3):249-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is caused by malignant immature lymphocytes.
  • Even though childhood ALL can be cured in a large number of patients, around 20% of the patients suffer a relapse after chemotherapy.
  • Given the high plasticity of cells, we searched for leukemia-associated genetic aberrations and immunoglobulin (IG) gene rearrangements in mesenchymal stem cells (MSC) from childhood B-cell precursor ALL patients.
  • MSC from all ten ALL patients analyzed presented the chromosomal translocations that had been detected in leukemia cells (TEL-AML1, E2A-PBX1, or MLL rearrangement).
  • Leukemia-specific IG gene rearrangements were detected in the MSC from three ALL patients.
  • The detection of leukemia-associated genetic aberrations in MSC indicates a clonal relationship between MSC and leukemia cells and suggests their involvement in the pathogenesis and/or pathophysiology of childhood ALL.
  • [MeSH-major] Mesenchymal Stromal Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Mol Med (Berl). 2010 Mar;88(3):219-22 [20135087.001]
  • [Cites] Leukemia. 1999 Dec;13(12):1901-28 [10602411.001]
  • [Cites] Cell Death Differ. 2009 May;16(5):749-57 [19219067.001]
  • [Cites] Leukemia. 1999 Jan;13(1):110-8 [10049045.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Bone. 1996 Nov;19(5):421-8 [8922639.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] Genes Dev. 1991 Mar;5(3):358-68 [1672117.001]
  • [Cites] Nat Rev Immunol. 2006 Feb;6(2):107-16 [16491135.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):257-68 [17981026.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9142-9 [17909019.001]
  • [Cites] Exp Hematol. 1996 Jan;24(1):1-10 [8536785.001]
  • [Cites] Hum Gene Ther. 1997 Sep 20;8(14 ):1695-700 [9322872.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):618-30 [8600166.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):993-1003 [16448696.001]
  • [Cites] PLoS Biol. 2007 Mar;5(3):e43 [17298184.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):497-510 [18598159.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):89-91 [12742162.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):483-95 [18538732.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3271-8 [8193362.001]
  • [Cites] Cell. 2008 Apr 18;133(2):250-64 [18423197.001]
  • [Cites] Blood. 2009 Apr 2;113(14 ):3287-96 [19147788.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1515-27 [19357701.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] J Cell Sci. 2006 Apr 15;119(Pt 8):1477-82 [16551697.001]
  • [Cites] Leukemia. 2009 Apr;23(4):664-72 [19151777.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2238-47 [8161789.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3644-54 [9218805.001]
  • [Cites] Blood. 2004 May 15;103(10):3798-804 [14656882.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2753-65 [16931776.001]
  • [Cites] Cell. 2007 Jul 13;130(1):63-75 [17599403.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):339-45 [12634724.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1377-88 [17604725.001]
  • [Cites] Methods Mol Med. 2004;91:175-82 [14573937.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] N Engl J Med. 2004 Jul 15;351(3):250-9 [15254283.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Lancet. 2000 May 13;355(9216):1688-91 [10905245.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):3-6 [16270377.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):542-5 [11932747.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):413-20 [12163366.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1978-82 [9369435.001]
  • [Cites] Blood. 1971 Jul;38(1):81-6 [5283675.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Blood. 1978 Jun;51(6):1039-44 [274158.001]
  • (PMID = 20155409.001).
  • [ISSN] 1432-1440
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


56. Karimova EJ, Kaste SC: MR imaging of osteonecrosis of the knee in children with acute lymphocytic leukemia. Pediatr Radiol; 2007 Nov;37(11):1140-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging of osteonecrosis of the knee in children with acute lymphocytic leukemia.
  • This essay illustrates various patterns of progression of osteonecrosis of the knee and the relationship between early MR imaging findings and radiologic outcome in children with acute lymphocytic leukemia.
  • [MeSH-major] Image Enhancement / methods. Knee Joint / pathology. Magnetic Resonance Imaging / methods. Osteonecrosis / diagnosis. Osteonecrosis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2003 Aug;181(2):545-9 [12876044.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(4):683-9 [17169552.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):370-8 [15565553.001]
  • [Cites] J Bone Joint Surg Br. 1991 Jan;73(1):68-72 [1991778.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3930-6 [15459215.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):400-8 [14985880.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Clin Radiol. 1998 Feb;53(2):131-6 [9502090.001]
  • [Cites] Clin Orthop Relat Res. 2006 Feb;443:273-9 [16462451.001]
  • [Cites] Clin Orthop Relat Res. 2002 Dec;(405):14-23 [12461352.001]
  • [Cites] Radiology. 1999 Dec;213(3):715-22 [10580944.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):260-5 [9251731.001]
  • [Cites] Pediatr Radiol. 1990;20(4):272-6 [2336289.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):11-7 [9917747.001]
  • [Cites] Acta Orthop Scand. 1998 Dec;69(6):598-602 [9930105.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):477-82 [16423956.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):363-8 [12540435.001]
  • [Cites] Radiology. 1987 Mar;162(3):709-15 [3809484.001]
  • [Cites] J Bone Joint Surg Br. 2000 Aug;82(6):837-41 [10990307.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Jul-Aug;15(4):307-15 [9658431.001]
  • [Cites] Klin Padiatr. 2003 Nov-Dec;215(6):332-7 [14677098.001]
  • [Cites] Clin Radiol. 2004 Dec;59(12 ):1079-93 [15556590.001]
  • [Cites] Expert Opin Biol Ther. 2005 Apr;5(4):437-42 [15934823.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):470-6 [16423955.001]
  • [Cites] Radiol Clin North Am. 2005 Jul;43(4):655-72, vii-viii [15893529.001]
  • [Cites] J Bone Joint Surg Am. 2000 Sep;82(9):1279-90 [11005519.001]
  • (PMID = 17768614.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / R01-CA20180
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 27
  •  go-up   go-down


57. Stachel D, Albert M, Meilbeck R, Kreutzer B, Haas RJ, Schmid I: Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL). Eur J Med Res; 2006 Mar 27;11(3):102-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
  • Samples from 49 consecutive pediatric patients with B cell precursor acute lymphocytic leukemia (BCP ALL) were analyzed by semiquantitative RT-PCR.
  • We identified interleukin (IL)-10 expression as a significant adverse prognostic indicator in childhood BCP-ALL.
  • Taqman RT-PCR of sorted cell populations showed that IL-10 mRNA was synthetized almost exclusively by NK or T cells.
  • These findings emphasize the role of the immune system for the outcome of childhood ALL.
  • [MeSH-major] Bone Marrow Cells / immunology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Cytokines / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Th2 Cells / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751110.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / CD86 protein, human; 0 / Cytokines; 0 / Interleukin-1; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


58. Robazzi TC, Barreto JH, Silva LR, Santiago MB, Mendonça N: Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil. J Pediatr Hematol Oncol; 2007 Sep;29(9):622-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil.
  • OBJECTIVE: This study was to determine the prevalence and characteristics of the osteoarticular manifestations on initial clinical presentation of acute leukemias (ALs) on childhood in the state of Bahia, Brazil.
  • RESULTS: Acute lymphocytic leukemia (ALL) was diagnosed in 313 (77.1%) patients and acute myeloid leukemia (AML), in 93 (22.9%) patients, including 241 males (59.4%) and 165 females (40.6%).
  • Prior referral to our center, the most frequent initial diagnosis was anemia (15.8%), leukemia (15.0%), amygdalitis (3.7%), and rheumatic fever (2.7%).
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Osteoarthritis / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Brazil. Child. Child, Preschool. Female. Humans. Infant. Male

  • MedlinePlus Health Information. consumer health - Osteoarthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805037.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Garcia-Manero G, Yang H, Kuang SQ, O'Brien S, Thomas D, Kantarjian H: Epigenetics of acute lymphocytic leukemia. Semin Hematol; 2009 Jan;46(1):24-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetics of acute lymphocytic leukemia.
  • Aberrant epigenetic lesions, in particular DNA methylation of promoter associated CpG islands, are common in acute lymphocytic leukemia (ALL).
  • (3) better understanding of the differences between pediatric and adult ALL; and (4) new therapeutic interventions by incorporating agents with hypomethylating activity to conventional chemotherapeutic programs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1997 Nov 20;15(21):2609-14 [9399648.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Hematol Cell Ther. 1999 Feb;41(1):19-26 [10193642.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3432-3; author reply 3433-4 [12412576.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):695-702 [12548613.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] Blood. 2004 Jan 15;103(2):743-6 [14702288.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2000-6 [15026336.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):707-13 [15226763.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(4):203-10 [2473850.001]
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Leukemia. 1995 May;9(5):915-21 [7769856.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):973-77 [8640788.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):832-6 [9041181.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):837-41 [9041182.001]
  • [Cites] Leukemia. 1997 Mar;11 Suppl 1:S24-7 [9130688.001]
  • [Cites] Leukemia. 1997 Jul;11(7):971-8 [9204977.001]
  • [Cites] Leukemia. 1999 Jun;13(6):884-90 [10360377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3352-6 [10416592.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1113-20 [10419905.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1165-72 [15756280.001]
  • [Cites] Leuk Res. 2005 Jul;29(7):739-48 [15927669.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2347-50 [16208412.001]
  • [Cites] Cancer Invest. 2005;23(7):635-42 [16305991.001]
  • [Cites] Leukemia. 2006 Feb;20(2):264-71 [16357833.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):137-44 [16846474.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3895-903 [16921040.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Biotechniques. 2006 Dec;41(6):734-9 [17191619.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1439-48 [16936778.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2617-25 [17363581.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Leukemia. 2007 May;21(5):906-11 [17344919.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8511-8 [17875690.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2302-8 [17596541.001]
  • [Cites] Nat Struct Mol Biol. 2008 Mar;15(3):268-79 [18311151.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1095-105 [18323801.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1942-9 [10706859.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4243-8 [11106238.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Blood. 2001 May 1;97(9):2823-9 [11313277.001]
  • [Cites] Leukemia. 2001 Apr;15(4):575-82 [11368359.001]
  • [Cites] Br J Haematol. 2001 May;113(2):329-38 [11380396.001]
  • [Cites] Nature. 2001 Nov 15;414(6861):258-61 [11713509.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2291-6 [11895758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3529-34 [11891335.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2741-9 [11965547.001]
  • (PMID = 19100365.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R21 CA126457; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / CA126457; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA 100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS89419; NLM/ PMC3833728
  •  go-up   go-down


60. Wang Y, Lin D, Wang DH, Ku ZF, Liu JZ, Liu XR, Wang JX, Wang M: [The expression of midkine in acute leukemia and its significance]. Zhonghua Xue Ye Xue Za Zhi; 2008 Aug;29(8):544-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of midkine in acute leukemia and its significance].
  • OBJECTIVE: To analyze the expression of midkine (MK) gene in acute leukemia patients, and explore the relationship between the gene and leukemia.
  • METHODS: The MK gene expression levels were detected by real-time quantitative RT-PCR (RQ-RT-PCR) in bone marrow (BM) of 181 acute leukemia (AL) patients and 31 normal controls.
  • The expression of MK showed a notable increase in all B-ALL subtypes (including pro-B-ALL, common-B-ALL and pre-B-ALL) as well as in adult and childhood B-ALL patients (P < 0.01).
  • CONCLUSION: MK gene expression is increased with different levels in B-ALL, M2 and M3 patients, which provides novel insights into the leukemogenesis of acute leukemia.
  • [MeSH-major] Cytokines / metabolism. Leukemia / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Child. Child, Preschool. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112919.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; 137497-38-2 / midkine
  •  go-up   go-down


61. Azevedo-Silva F, Camargo Bd, Pombo-de-Oliveira MS: Implications of infectious diseases and the adrenal hypothesis for the etiology of childhood acute lymphoblastic leukemia. Braz J Med Biol Res; 2010 Mar;43(3):226-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of infectious diseases and the adrenal hypothesis for the etiology of childhood acute lymphoblastic leukemia.
  • Acute leukemia is the most frequent cancer in children.
  • Recently, a new hypothesis was proposed for the pathogenesis of childhood acute lymphoblastic leukemia (ALL).
  • The so-called 'adrenal hypothesis' emphasized the role of endogenous cortisol in the etiology of B-cell precursor ALL.
  • The adrenal hypothesis proposes that the risk of childhood B-cell precursor ALL is reduced when early childhood infections induce qualitative and quantitative changes in the hypothalamus-pituitary-adrenal axis.


62. Shimonodan H, Nagayama J, Nagatoshi Y, Hatanaka M, Takada A, Iguchi H, Oda Y, Okamura J: Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature. Pediatr Blood Cancer; 2005 Sep;45(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphocytic leukemia in adolescence with multiple osteolytic lesions and hypercalcemia mediated by lymphoblast-producing parathyroid hormone-related peptide: a case report and review of the literature.
  • BACKGROUND: Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is rarely observed.
  • [MeSH-major] Hypercalcemia / etiology. Osteolysis / etiology. Parathyroid Hormone-Related Protein / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15700250.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  • [Number-of-references] 37
  •  go-up   go-down


63. Herron MD, O'reilly MA, Vanderhooft SL: Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia. Pediatr Dermatol; 2005 Sep-Oct;22(5):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia.
  • We report five children with acute lymphocytic leukemia on maintenance chemotherapy who had Demodex folliculitis.
  • We suggest that treatment of Demodex folliculitis in children with acute lymphocytic leukemia is more difficult than is suggested in the literature.
  • Newer sodium sulfacetamide/sulfur formulations should be considered when treating this condition, particularly in children with acute lymphocytic leukemia.
  • [MeSH-major] Anti-Infective Agents / administration & dosage. Folliculitis / drug therapy. Mite Infestations / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. PERMETHRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190988.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antineoplastic Agents; 0 / Sulfur Compounds; 140QMO216E / Metronidazole; 4965G3J0F5 / Sulfacetamide; 509F88P9SZ / Permethrin
  •  go-up   go-down


64. Ebeid E, Kamel M, Moussa H, Galal U: ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia. J Egypt Natl Canc Inst; 2008 Jun;20(2):121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
  • BACKGROUND: Zeta-chain-associated protein (ZAP- 70) is a 70kD adaptor protein that acts quickly after T cell activation to propagate signal.
  • The role of ZAP-70 in Tcell function is well established, and in the previous years, this molecule was considered to be T-cell specific.
  • Interest in ZAP-70 has grown since it has been shown, through gene expression profiling, that it is expressed in a subset of cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • PURPOSE: The aim of this study was to investigate the expression of ZAP-70 in leukemic blasts of 50 newly diagnosed patients of B-lineage acute lymphoblastic leukemia (ALL), and to assess the correlation between ZAP-70 expression and various prognostic factors and outcome.
  • PATIENTS AND METHODS: This study included 50 pediatric patients with newly diagnosed B-lineage ALL.
  • They were 28 males (56% ) and 22 females (44% ) presented to the Pediatric Oncology Department, National Cancer Institute, Cairo University, during the period from 2005 to 2007.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029467.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


65. Chatzidakis K, Goulas A, Athanassiadou-Piperopoulou F, Fidani L, Koliouskas D, Mirtsou V: Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr Blood Cancer; 2006 Aug;47(2):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients.
  • BACKGROUND: As of late, a number of studies have focused on the association of the gene for methyletetrahydrofolate reductase (MTHFR) with risk for acute lymphoblastic leukemia (ALL) in children and in adults, as well as with response to chemotherapy.
  • PROCEDURE: We have analyzed the MTHFR C677T polymorphism in 52 patients and 88 control individuals, all ethnic Greek residents of northern Greece, and examined the association of this polymorphism with (a) susceptibility to childhood ALL and (b) the distribution of average plasma alanine aminotransferase (ALT) levels, white blood cell counts (WBC), and hemoglobin levels (Hb) during the induction and consolidation phases of treatment.
  • In addition, we observed a general tendency towards lower values in all three parameters studied, associated with the MTHFR 677CC genotype, which was more evident in the transition from the induction to the consolidation phase, indicating that MTHFR genotyping may be of prognostic value in the early phase of treatment for childhood ALL, in our population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123993.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


66. Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2009 Jan;26(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia.
  • The analysis of differential microRNA expression profiles may be a powerful tool to allow us insight on the mechanisms of childhood B-cell precursor acute lymphoblastic leukemia (pre-B-ALL).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Child, Preschool. Computational Biology. Gene Expression Profiling. Hematopoiesis / genetics. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


67. Taylor M, Harrison C, Eden T, Birch J, Greaves M, Lightfoot T, Hussain A, UKCCS Investigators: HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention. Cancer Immunol Immunother; 2008 Jan;57(1):53-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention.
  • Most childhood B cell precursor (BCP) acute lymphoblastic leukaemia (ALL) cases carry the reciprocal translocation t(12;21)(p13;q22) ( approximately 25%), or a high hyperdiploid (HeH) karyotype (30%).
  • Based on our previous analysis of HLA-DP in childhood ALL, and evidence from in vitro studies that TEL-AML1 can activate HLA-DP-restricted T cell responses, we hypothesised that the development of TEL-AML1+ ALL might be influenced by the child's DPB1 genotype.
  • To test this, we analysed the frequency of six HLA-DPB1 supertypes in a population-based series of childhood leukaemias (n = 776) classified by their karyotype (TEL-AML1+, HeH and others), in comparison with newborn controls (n = 864).
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Genetic Predisposition to Disease. HLA-DP Antigens / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17622527.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / HLA-DP Antigens; 0 / HLA-DP beta-Chains; 0 / HLA-DPB1 antigen; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


68. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We studied the relationship between molecular-cytogenetic abnormalities and T-cell development stage to investigate whether arrest at specific stages can explain the prognostic significance of specific abnormalities.
  • We extensively studied 72 pediatric T-ALL cases for genetic abnormalities and expression of transcription factors, NOTCH1 mutations and expression of specific CD markers.
  • Classification into T-cell developmental subgroups was not predictive for outcome.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Lineage. Child. Female. Homeodomain Proteins / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Mutation / genetics. Oncogene Proteins, Fusion / genetics. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


69. Mazor D, Abucoider A, Meyerstein N, Kapelushnik J: Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: the impact of oxidative stress. Pediatr Blood Cancer; 2008 Nov;51(5):613-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: the impact of oxidative stress.
  • BACKGROUND: Pediatric ALL patients are subjected to an aggressive and continuous chemotherapy protocol, while solid tumor patients have a less intensive treatment.
  • This oxidative stress may lead to cell death or greater sensitivity of the tumor cell to therapy, with better outcome for pediatric patients with ALL.
  • [MeSH-major] Antioxidants / metabolism. Neoplasms / blood. Oxidative Stress / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18623225.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Sulfhydryl Compounds
  •  go-up   go-down


70. Reichmann-Decker A, DePrince AP, McIntosh DN: Affective responsiveness, betrayal, and childhood abuse. J Trauma Dissociation; 2009;10(3):276-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Affective responsiveness, betrayal, and childhood abuse.
  • We predicted that women who reported childhood abuse by close others would show alterations in affective responsiveness relative to their peers.
  • We tested 100 undergraduate women who reported histories of (a) childhood sexual or physical abuse by someone close, such as a parent (high-betrayal);.
  • (b) childhood abuse by someone not close (low-betrayal); or (c) no abuse in childhood (no-abuse).

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Child Abuse.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585337.001).
  • [ISSN] 1529-9740
  • [Journal-full-title] Journal of trauma & dissociation : the official journal of the International Society for the Study of Dissociation (ISSD)
  • [ISO-abbreviation] J Trauma Dissociation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Forestier E, Gauffin F, Andersen MK, Autio K, Borgström G, Golovleva I, Gustafsson B, Heim S, Heinonen K, Heyman M, Hovland R, Johannsson JH, Kerndrup G, Rosenquist R, Schoumans J, Swolin B, Johansson B, Nordgren A, Nordic Society of Pediatric Hematology and Oncology, Swedish Cytogenetic Leukemia Study Group, NOPHO Leukemia Cytogenetic Study Group: Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer; 2008 Feb;47(2):149-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)-positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature.
  • Although dic(9;20)(p13.2;q11.2) is a characteristic abnormality in childhood B-cell precursor acute lymphoblastic leukemias (BCP ALL), little is known about its clinical impact or the type and frequency of additional aberrations it may occur together with.
  • We here review the clinical and cytogenetic features of a Nordic pediatric series of 24 patients with dic(9;20)-positive BCP ALL diagnosed 1996-2006, constituting 1.3% of the BCP ALL, as well as 47 childhood cases from the literature.
  • Consistent immunophenotypic features of the Nordic cases included positivity for HLA-DR, CD10, CD19, CD20, and CD22 and negativity for T-cell and myeloid markers; no detailed immunophenotypes were reported for the previously published cases.
  • The median patient age was 3 years, the female/male ratio was 2.0, the median white blood cell count was 24 x 10(9)/l, 11% had central nervous system involvement, and 5% had a mediastinal mass at diagnosis.
  • [MeSH-major] Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 9 / genetics. Cytogenetics. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17990329.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


72. Hadziselimovic F: Early successful orchidopexy does not prevent from developing azoospermia. Int Braz J Urol; 2006 Sep-Oct;32(5):570-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The incidence of Ad spermatogonia (stem cells for fertility) was assessed in 20 cryptorchid patients, all of whom had a successful orchidopexy in childhood but developed azoospermia following puberty.
  • The patients were classified into 2 groups according to the time of surgery: A = < 21 months of age (n = 5, mean = 10.7 +/- 8.6 months) and B = during childhood (n = 15, mean = 10.1 +/- 3 years).

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081328.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


73. Wehrli LA, Braun J, Buetti LN, Hagleitner N, Hengartner H, Kühne T, Lüer S, Ozsahin H, Popovic MB, Niggli FK, Betts DR, Bourquin JP: Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2009 Feb;189(1):29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
  • Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification.
  • We compared the karyotypes from 436 nonselected B-cell precursor ALL patients at initial diagnosis and of 76 patients at first relapse.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. Infant. Karyotyping. Male. Recurrence. Translocation, Genetic. Treatment Outcome


74. Healy J, Richer C, Bourgey M, Kritikou EA, Sinnett D: Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. Haematologica; 2010 Sep;95(9):1608-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia.
  • Although childhood acute lymphoblastic leukemia is the most common pediatric cancer, its etiology remains poorly understood.
  • In an attempt to replicate the findings of 2 recent genome-wide association studies in a French-Canadian cohort, we confirmed the association of 5 SNPs [rs7073837 (P=4.2 x 10(-4)), rs10994982 (P=3.8 x 10(-4)), rs10740055 (P=1.6 x 10(-5)), rs10821936 (P=1.7 x 10(-7)) and rs7089424 (P=3.6 x 10(-7))] in the ARID5B gene with childhood acute lymphoblastic leukemia.
  • We also confirmed a selective effect for B-cell acute lymphoblastic leukemia with hyperdiploidy and report a putative gender-specific effect of ARID5B SNPs on acute lymphoblastic leukemia risk in males.
  • This study provides a strong rationale for more detailed analysis to identify the causal variants at this locus and to better understand the overall functional contribution of ARID5B to childhood acute lymphoblastic leukemia susceptibility.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1997 Sep;21(9):817-23 [9393596.001]
  • [Cites] Nucleic Acids Res. 1996 May 1;24(9):1695-701 [8649988.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1496-501 [10029576.001]
  • [Cites] Genetics. 2005 Nov;171(3):1321-30 [15944347.001]
  • [Cites] Blood. 2007 Jan 15;109(2):683-92 [17008550.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):1-20, ix [18242313.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5515-23 [18334672.001]
  • [Cites] Leuk Res. 2009 Jun;33(6):759-63 [19101034.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1001-5 [19684603.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):1006-10 [19684604.001]
  • [Cites] Blood. 2010 Mar 4;115(9):1765-7 [20042726.001]
  • [Cites] Leukemia. 2010 Apr;24(4):894-6 [20054350.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):786-92 [17454638.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1941-53 [10711237.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):230-6 [11774269.001]
  • [Cites] Cell Growth Differ. 2002 Mar;13(3):95-106 [11959810.001]
  • [Cites] Genet Epidemiol. 2002 Nov;23(4):426-43 [12432508.001]
  • [Cites] Genet Epidemiol. 2004 Jul;27(1):21-32 [15185400.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):259-66 [9634505.001]
  • (PMID = 20460642.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / ARID5B protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2930966
  •  go-up   go-down


75. Paulsson K, Johansson B: High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer; 2009 Aug;48(8):637-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploidy (51-67 chromosomes) is the most common cytogenetic abnormality pattern in childhood B-cell precursor acute lymphoblastic leukemia (ALL), occurring in 25-30% of such cases.
  • Despite the high frequency of this karyotypic subgroup, many questions remain regarding the epidemiology, etiology, presence of other genetic changes, the time and cell of origin, and the formation and pathogenetic consequences of high hyperdiploidy.
  • However, during the last few years, several studies have addressed some of these important issues, and these, as well as previous reports on high hyperdiploid childhood ALL, are reviewed herein.
  • [MeSH-major] Chromosome Aberrations. Diploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma


76. Lee DS, Kim YR, Cho HK, Lee CK, Lee JH, Cho HI: The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet; 2005 Oct 15;162(2):176-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of TEL/AML1 rearrangement and cryptic deletion of the TEL gene in adult acute lymphoblastic leukemia (ALL).
  • TEL/AML1 (also known as ETV6/RUNX1) rearrangement is the most frequent genetic change in childhood B-acute lymphoblastic leukemia (ALL) and is associated with a favorable prognosis.
  • TEL/AML1 rearrangement is not unique in childhood ALL, and cryptic TEL deletion without TEL/AML1 rearrangement was more frequent than the TEL/AML1 rearrangement in adult ALL.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Deletion. Gene Rearrangement. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213368.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


77. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia.
  • BACKGROUND: Children with acute lymphocytic leukemia (ALL) are at high risk for developing hyperglycemia.
  • [MeSH-major] Hyperglycemia / complications. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18523991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


78. Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M: [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jan;30(1):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ALL-XH-99 protocol in the treatment of childhood T-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To analyze the incidence, clinical characteristics and prognosis of childhood T-cell acute lymphoblastic leukemia (T-ALL).
  • RESULTS: Of 305 childhood ALL patients, 43 were T-ALL.
  • In comparison with that of B cell ALL (B-ALL), the percentages of age older than 10 years, initial WBC count more than 50 x 10(9)/ L, prednisone poor response (PPR), and failed to achieve remission at day 19 of induction chemotherapy in the T-ALLs were all higher.
  • CONCLUSION: There were statistic differences between T-cell and B-cell childhood ALLs in age, initial WBC count, early response to therapy, and eight-year EFS and RFS.
  • Childhood T-ALL was associated with a worse prognosis than other sub-types of childhood ALL.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunophenotyping. Infant. Karyotyping. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563031.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


79. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • Accordingly, they were able to analyze 8 of 10 individuals with DS and a BCP ALL, including 2 who suffered from a TEL/AML1+ leukemia.
  • Based on this observation we concluded that individuals with a constitutional trisomy 21 may have the similar likelihood to develop a TEL/AML1+ leukemia as BCP ALL patients without this specific predisposingfactor.
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


80. Lu Y, Sun LR, Pang XY, Lu ZH, Sui AH: [Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases]. Ai Zheng; 2007 Jan;26(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infection status and clinical significance of Epstein-Barr virus in pediatric leukemia---a report of 35 cases].
  • This study was to detect EBV infection in pediatric leukemia, and to explore its clinical significance.
  • METHODS: EBV DNA in peripheral blood mononuclear cells in 35 pediatric leukemia patients, including 26 cases of acute lymphoblastic leukemia (ALL) (24 received initial treatment and 2 received retreatment), 8 cases of acute non-lymphocytic leukemia (ANLL) and 1 case of chronic lymphocytic leukemia (CLL), and in 14 healthy children was detected by fluorescent quantitative polymerase chain reaction (FQ-PCR).
  • RESULTS: EBV DNA was detected in 8 (22.86%) of the 35 pediatric leukemia patients.
  • CONCLUSIONS: Pediatric leukemia patients with EBV infection have higher incidence of peripheral leukocytosis and hepatosplenomegaly.
  • [MeSH-major] Epstein-Barr Virus Infections. Leukemia, Myeloid, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Child. Child, Preschool. DNA, Viral / blood. Female. Hepatomegaly / etiology. Herpesvirus 4, Human / genetics. Humans. Infant. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Leukocytosis / etiology. Male. Prednisone / therapeutic use. Remission Induction. Splenomegaly / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222368.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / DNA, Viral; VB0R961HZT / Prednisone
  •  go-up   go-down


81. Tie LJ, Gu LJ, Chen J, Jiang LM, Dong L, Pan C, Ye H, Song DL, Xue HL, Tang JY, Wang YP, Chen J: [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2006 Feb;27(2):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To assess the prognostic value of minimal residual disease (MRD) in childhood B-cell acute lymphoblastic leukemia (ALL) after induction chemotherapy.
  • CONCLUSION: The MRD level at achieving CR is one of important prognostic factor in the treatment of childhood B-cell ALL, and might be used to assess the early treatment response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, B-Cell / drug therapy. Neoplasm, Residual

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732969.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


82. Chang P, Kang M, Xiao A, Chang J, Feusner J, Buffler P, Wiemels J: FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer; 2010 Sep 27;10:513
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.
  • BACKGROUND: Mutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor prognosis among various subtypes of leukemia.
  • We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia patients from Northern California.
  • METHODS: We screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs) among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth using sensitive "backtracking" methods.
  • RESULTS: We determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441 acute lymphocytic leukemias (ALLs, 2%).

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Blood. 2010 Oct 14;116(15):2752-8 [20592250.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1217-20 [16642044.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1085-9 [16533526.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):64-70 [17943971.001]
  • [Cites] J Natl Cancer Inst Monogr. 2008;(39):87-90 [18648011.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1692-7 [18548099.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):212-9 [18940823.001]
  • [Cites] Methods Mol Biol. 2009;538:7-27 [19277581.001]
  • [Cites] Drug Resist Updat. 2009 Jun;12(3):81-9 [19467916.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2722-4 [10753857.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11 [12447846.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Leukemia. 1996 Feb;10(2):213-24 [8637229.001]
  • [Cites] Genes Chromosomes Cancer. 1996 May;16(1):40-5 [9162196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Med Oncol. 2009 Dec;26(4):460-2 [19085113.001]
  • [Cites] Leukemia. 2010 May;24(5):924-31 [20237506.001]
  • [Cites] Blood Cells Mol Dis. 2010 Oct 15;45(3):186-91 [20688547.001]
  • [Cites] BMC Cancer. 2006;6:100 [16630339.001]
  • (PMID = 20875128.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / R01 CA089032-06; United States / NIEHS NIH HHS / ES / P42ES0470; United States / NCI NIH HHS / CA / R01 CA089032-05; United States / NCI NIH HHS / CA / R01CA89032; United States / NIEHS NIH HHS / ES / R01ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2955609
  •  go-up   go-down


83. Krstic AD, Impera L, Guc-Scekic M, Lakic N, Djokic D, Slavkovic B, Storlazzi CT: A complex rearrangement involving cryptic deletion of ETV6 and CDKN1B genes in a case of childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2009 Dec;195(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complex rearrangement involving cryptic deletion of ETV6 and CDKN1B genes in a case of childhood acute lymphoblastic leukemia.
  • We report on a case of childhood B-cell lineage acute lymphoblastic leukemia (ALL).
  • The deleted segment on 12p contains several genes, among the tumor suppressor genes ETV6 and CDKN1B, which are frequently involved in 12p abnormalities in childhood ALL.
  • Thus, the present study documents the loss of both ETV6 and CDKN1B genes accompanying the occurrence of a complex rearrangement involving chromosomes 3 and 12 in a case of childhood ALL.
  • [MeSH-major] Gene Deletion. Intracellular Signaling Peptides and Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Genet Cytogenet. 2010 Apr 1;198(1):76
  • (PMID = 19963112.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / ETS translocation variant 6 protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


84. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A: Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood; 2009 Apr 2;113(14):3287-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD133 on leukemia-initiating cells in childhood ALL.
  • Optimization of therapy for childhood acute lymphoblastic leukemia (ALL) requires a greater understanding of the cells that proliferate to maintain this malignancy because a significant number of cases relapse, resulting from failure to eradicate the disease.
  • We investigated expression of CD133, CD19, and CD38 in pediatric B-ALL.
  • Furthermore, these CD133(+)/CD19(-) ALL cells were more resistant to treatment with dexamethasone and vincristine, key components in childhood ALL therapy, than the bulk leukemia population.
  • These data suggest that leukemia-initiating cells in childhood B-ALL have a primitive CD133(+)/CD19(-) and CD38(-) phenotype.
  • [MeSH-major] Antigens, CD / metabolism. Glycoproteins / metabolism. Neoplastic Stem Cells / metabolism. Peptides / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Animals. Antigens, CD19 / metabolism. Antigens, CD38 / metabolism. Cell Proliferation. Child. Child, Preschool. Gene Rearrangement, T-Lymphocyte / physiology. Humans. Immunoglobulin Heavy Chains / genetics. Membrane Glycoproteins / metabolism. Mice. Mice, Inbred NOD. Mice, SCID. Phenotype. Transplantation, Heterologous. Tumor Cells, Cultured

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Apr 30;113(18):4476-7; author reply 4477 [19407001.001]
  • (PMID = 19147788.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Glycoproteins; 0 / Immunoglobulin Heavy Chains; 0 / Membrane Glycoproteins; 0 / Peptides; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


85. Tahrani AA, Cramp C, Moulik P: The development of non-insulin-dependent diabetes after total body irradiation and bone marrow transplantation in adolescence: a case report and literature review. Pediatr Diabetes; 2006 Jun;7(3):173-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 6-yr-old-child received total body irradiation (TBI) and bone marrow transplantation (BMT) for relapsed acute lymphocytic leukemia.
  • Islet cell and anti-GAD antibodies were negative.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Diabetes Mellitus, Type 2 / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Whole-Body Irradiation / adverse effects


86. Campbell LK, Scaduto M, Sharp W, Dufton L, Van Slyke D, Whitlock JA, Compas B: A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2007 Jul;49(1):65-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of the neurocognitive sequelae of treatment for childhood acute lymphocytic leukemia.
  • BACKGROUND: Impaired neurocognitive functioning is one increasingly recognized long-term consequence of childhood ALL treatment.
  • PROCEDURE: A comprehensive meta-analytic review of the long-term neurocognitive effects of childhood ALL was conducted.
  • Studies were included if they were published in English, reported original quantitative data on the post-treatment neurocognitive functioning of childhood ALL patients in first remission and control groups, and used neurocognitive measures with adequate psychometric properties and published normative data.
  • Neurocognitive assessment plays a critical role in determining what remedial or specialized instruction is needed in childhood ALL survivors and should be included as a standard part of long-term follow-up care.
  • [MeSH-major] Cognition Disorders / physiopathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628558.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Robinson KE, Livesay KL, Campbell LK, Scaduto M, Cannistraci CJ, Anderson AW, Whitlock JA, Compas BE: Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses. Pediatr Blood Cancer; 2010 Apr;54(4):585-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Working memory in survivors of childhood acute lymphocytic leukemia: functional neuroimaging analyses.
  • BACKGROUND: Research on the physical and psychological late effects of treatment of childhood cancer has led to the identification of significant long-term neurocognitive deficits experienced by some survivors, particularly in the areas of memory and executive functioning.
  • PROCEDURE: This study used functional neuroimaging techniques to examine working memory and executive functioning deficits of survivors of childhood acute lymphocytic leukemia (ALL), as compared to age- and gender-matched healthy controls.
  • CONCLUSIONS: These results support the theory of compensatory activation in necessary brain regions in order to complete tasks in pediatric ALL survivors, similar to that observed in multiple sclerosis patients.

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2002 Jun;125(Pt 6):1275-82 [12023316.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):88-92 [12461791.001]
  • [Cites] Biol Psychiatry. 2003 Mar 1;53(5):376-84 [12614990.001]
  • [Cites] Dev Psychol. 2003 Jul;39(4):761-76 [12859128.001]
  • [Cites] Hum Brain Mapp. 2003 Oct;20(2):51-8 [14505331.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1021:296-309 [15251900.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2082-90 [15341983.001]
  • [Cites] Child Dev. 2004 Sep-Oct;75(5):1357-72 [15369519.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):61-9 [15588597.001]
  • [Cites] Hum Brain Mapp. 2005 May;25(1):46-59 [15846822.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):357-63 [16179658.001]
  • [Cites] Cancer. 2005 Dec 1;104(11 Suppl):2557-64 [16247780.001]
  • [Cites] Hum Brain Mapp. 2006 Jan;27(1):28-36 [16001441.001]
  • [Cites] Hum Brain Mapp. 2006 May;27(5):392-401 [16596654.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1094:226-34 [17347354.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):65-73 [16628558.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):792-7 [18184841.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):99-104 [18322925.001]
  • (PMID = 19953649.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068485-13S4; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / CA068485; United States / NCI NIH HHS / CA / P30 CA068485-13S4
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS183910; NLM/ PMC2901833
  •  go-up   go-down


88. Kiss F, Buslig J, Szegedi I, Scholtz B, Kappelmayer J, Kiss C: Early relapse after rituximab chemoimmunotherapy. Pediatr Blood Cancer; 2008 Feb;50(2):372-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In relapsed/refractory childhood acute lymphoblastic leukemia (ALL) of the B-cell lineage rituximab, a monoclonal anti-CD20 antibody was used successfully in some cases.
  • We report on a 15-year-old female with relapsed CD20-positive B-cell progenitor ALL treated with rituximab because of positive minimal residual disease signals after chemotherapy, as checked by flow cytometry and real time quantitative-PCR.
  • The patient died with fulminant aspergillosis before hematopoietic stem cell transplantation could be performed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Flow Cytometry. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Humans. Neoplasm, Residual / pathology. Recurrence. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973316.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


89. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, Fedasenka UU: ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology; 2009 Aug;14(4):204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
  • Childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cells and chronic lymphocytic leukemia (CLL) cells of adults were studied.
  • No differences between expression of P-gp and BCRP and genes in primary and relapsed acute leukemia (AL) cells as well as in de novo and treated CLL samples were established.
  • Doxorubicine, rubomycinum and L-asparaginase resistance correlates with P-gp overexpression and increased function in pediatric AL whereas vincristine resistance might be associated with P-gp protein expression in AL samples and impared P-gp function in CLL lymphocytes only.
  • A tendency for the decreased doxorubicin cytotoxic activity was shown in BCRP-overexpressing cells both in children and adults leukemia.
  • Multifactorial ANOVA showed that P-gp/MDR1 and BCRP as well as their function could not be used as unconditional and universal predictors of leukemia cell drug resistance in vitro.
  • These results suggest that studied MDR transporter-proteins have a limited role per se in vitro and admittedly in vivo drug resistance estimated in leukemia patients or it is not yet fully understood unless would not be studied in aggregate.
  • In any event, the expression and function studies of the proteins under investigation when singularly considered do not have a crucial significance for impact on drug resistance evaluation in all leukemia patients.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette, Sub-Family B, Member 1 / biosynthesis. Leukemia / drug therapy. Leukemia / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family B. ATP Binding Cassette Transporter, Sub-Family G, Member 2. Acute Disease. Adolescent. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Drug Resistance, Neoplasm. Gene Expression. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635183.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Neoplasm Proteins
  •  go-up   go-down


90. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • RESULTS: In total, 243 patients with B-precursor and T-cell ALL were treated according to the protocols.
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Podgornik H, Debeljak M, Zontar D, Cernelc P, Prestor VV, Jazbec J: RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Oct 1;178(1):77-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
  • Amplification of RUNX1 (alias AML1) is a recurrent karyotypic abnormality in childhood acute lymphoblastic leukemia (ALL) that is generally associated with a poor outcome.
  • It does not occur with other primary chromosomal abnormalities in acute ALL.
  • AML1 amplification in acute myelogenous leukemia (AML) is a rare secondary event described mainly in therapy-related cases.
  • AML1 amplification was found in a 13-year-old patient with AML M4/M5 leukemia that occurred 5 years after she had been diagnosed with common B-cell ALL.
  • Conventional cytogenetic, fluorescent in situ hybridization (FISH), and polymerase chain reaction methods revealed no other chromosomal change expected to occur in a disease that we assumed to be a secondary leukemia.
  • While the first course of chemotherapy successfully eradicated the cell line with the t(12;21), the second cell line with AML1 amplification remained latent during the time of complete remission and reappeared with a different immunophenotype.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / genetics. Leukemia, B-Cell / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


92. Kikuchi A, Mori T, Fujimoto J, Kumagai M, Sunami S, Okimoto Y, Tsuchida M: Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol. Leuk Lymphoma; 2008 Apr;49(4):757-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children's Cancer Study Group NHL B9604 protocol.
  • From June 1996 to January 2001, 91 patients with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia up to 18 years of age were enrolled in Tokyo Children's Cancer Study Group (TCCSG) NHL B9604 protocol study.
  • The TCCSG NHL B9604 protocol achieved an excellent treatment outcome especially in patients with the most advanced disease (Group D: high BM blast cell burden and/or central nervous system involvement).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy


93. Talano JM, Casper JT, Camitta BM, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA: Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. Bone Marrow Transplant; 2006 Jan;37(2):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Children with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) have only a 20% event-free survival when treated with chemotherapy alone.
  • Graft-versus-host disease (GVHD) prophylaxis consisted of T-cell depletion (antibody T10B9 or OKT3 and complement) with post transplant cyclosporine (CSA).
  • Four developed grades III-IV acute GVHD.
  • [MeSH-major] Bone Marrow Transplantation. Donor Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273115.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


94. Stachel D, Albert M, Meilbeck R, Paulides M, Schmid I: Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep; 2007 Jan;17(1):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
  • In pediatric acute lymphocytic leukemia however, the expression of angiogenic molecules and its relation to prognosis and relapse are unknown.
  • Therefore, we prospectively analyzed 46 pediatric patients with precursor B cell acute lymphocytic leukemia by semi-quantitative RT-PCR for expression of the angiogenic molecules VEGF, VEGF-C, iNOS and TGF-beta and correlated relapse and survival data with the expression of these factors.
  • Angiogenic factors are expressed in the bone marrow of patients with pediatric B cell precursor ALL and VEGF is a potential candidate for therapeutic intervention as it is significantly higher expressed in children with late relapses.
  • The mRNA expression of iNOS in the surviving children possibly reflects an increased activity of the immune system against the leukemia which leads to a superior survival.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Burkitt Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143492.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


95. Al-Zein N, Boyce TG, Correa AG, Rodriguez V: Meningitis caused by lymphocytic choriomeningitis virus in a patient with leukemia. J Pediatr Hematol Oncol; 2008 Oct;30(10):781-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningitis caused by lymphocytic choriomeningitis virus in a patient with leukemia.
  • We report a case of 15-year-old girl with T-cell acute lymphoblastic leukemia who had fever, neutropenia, and severe headache while receiving maintenance chemotherapy.
  • Cerebrospinal fluid testing revealed a lymphocytic pleocytosis and no evidence of relapsed leukemia.
  • Meningitis caused by lymphocytic choriomeningitis virus was identified serologically.
  • Lymphocytic choriomeningitis virus is a rare cause of aseptic meningitis that should be considered in the symptomatic immunocompromised patient with an appropriate exposure history.
  • [MeSH-major] Lymphocytic Choriomeningitis / etiology. Lymphocytic choriomeningitis virus / isolation & purification. Meningitis, Aseptic / etiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011481.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Liu Y, Zhu P, Hu YM: [Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia].
  • OBJECTIVE: To clone IgHV genes from childhood B-ALL cells and identify CTL epitopes deduced from IgHV gene.
  • METHODS: Seven IgHV gene families were respectively amplified by PCR and directly sequenced for 37 childhood B-ALL cases.
  • CONCLUSION: IgHV genes in childhood B-ALL are of germline characteristics.
  • [MeSH-minor] Adolescent. Cell Proliferation. Child. Child, Preschool. Gene Rearrangement. HLA-A Antigens / immunology. HLA-A Antigens / metabolism. HLA-A2 Antigen. Humans. Infant. Oligopeptides / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946551.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Epitopes, T-Lymphocyte; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Oligopeptides
  •  go-up   go-down


97. Akbayram S, Doğan M, Akgün C, Erbey F, Caksen H, Oner AF: Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Target Oncol; 2010 Dec;5(4):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoclonal antibodies have provided new promise for patients with B-cell malignancies.
  • Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
  • In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin lymphoma, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab.
  • Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin lymphoma.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):218 [16847929.001]
  • [Cites] Pediatr Blood Cancer. 2009 May;52(5):664-6 [19142990.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):389-97 [11208830.001]
  • [Cites] Curr Opin Pediatr. 2008 Feb;20(1):17-22 [18197034.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Apr;25(4):327-9 [12679650.001]
  • [Cites] Lancet. 2001 Nov 3;358(9292):1511-3 [11705566.001]
  • [Cites] Curr Opin Oncol. 1998 Nov;10(6):548-51 [9818234.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Feb;24(2):160-3 [11998794.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):177-81 [18816698.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] J Pediatr. 2007 Apr;150(4):338-44, 344.e1 [17382107.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):125-7 [12358915.001]
  • [Cites] Br J Haematol. 2004 May;125(3):414-5 [15086431.001]
  • [Cites] In Vivo. 2009 May-Jun;23(3):475-8 [19454517.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):300-1 [11920807.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2287-95 [17277134.001]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):442-4 [11984808.001]
  • [Cites] Clin Exp Rheumatol. 2006 Jan-Feb;24(1):65-9 [16539821.001]
  • [Cites] Blood. 2003 May 15;101(10):3857-61 [12531800.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1S2):41-47 [28140091.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):339-44 [12746167.001]
  • [Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] J Clin Oncol. 2010 Jul 1;28(19):3115-21 [20516455.001]
  • (PMID = 20859698.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


98. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW: Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol; 2009 Dec;132(6):940-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.
  • Morphologic distinction of leukemic lymphoblasts in B acute lymphoblastic leukemia (B-ALL) from their nonneoplastic counterparts in bone marrow (hematogones) can be difficult.
  • Of 200 cases, 9.0% aberrantly expressed T cell-associated antigens.
  • There were significant differences in antigen-expression patterns between adult and pediatric B-ALL.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunophenotyping / methods. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Precursor Cells, B-Lymphoid / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, Rubnitz JE, Hijiya N, Howard SC, Cheng C, Pui CH: Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood; 2006 Nov 15;108(10):3302-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.
  • CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL).
  • We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies.
  • There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex.
  • These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.


100. Luczyński W, Krawczuk-Rybak M, Stasiak-Barmuta A: [Experimental and selected clinical aspects of active immunotherapy in leukemia]. Postepy Hig Med Dosw (Online); 2006;60:379-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental and selected clinical aspects of active immunotherapy in leukemia].
  • The aim of the review is to summarize current knowledge concerning active immunotherapy in leukemia.
  • The molecular mechanisms and selected clinical implications of different cancer vaccines used in pediatric and adult leukemias are discussed.
  • Cells of acute lymphoblastic leukemia and chronic lymphocytic leukemia can be induced into antigen-presenting cells with the CD40 ligation system.
  • In many studies it was confimed that these cells stimulate auto- and/or allogeneic T-cell response.
  • Similar effects using different cytokines such as GM-CSF, TNF-alpha, and IL-4 can be observed in acute myeloid leukemia and myelodysplastic syndromes.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885908.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Number-of-references] 51
  •  go-up   go-down






Advertisement